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  - ABC: Atp-binding cassette transporters
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  - BBB: Blood-brain barrier
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  - CBP: CREB-Binding Protein
  - Cdk5: Cyclin dependent kinase 5
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  - Grb2: Growth factor receptor-bound protein 2
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Las vías de señalización de la insulina e IGF-1 se encuentran entre las más estudia-
das en el organismo. Su regulación es crucial para el correcto funcionamiento de procesos 
esenciales, como la homeostasis metabólica o el desarrollo y crecimiento celular, motivo por 
el cual han sido estudiadas de forma exhaustiva. Sin embargo se desconocen los motivos 
exactos por los que sus funciones se ven alteradas ante determinadas circuntancias. Distin-
tas publicaciones apuntan a que, además de sus numerosas funciones en todo el organis-
mo, la insulina juega un papel importante en el cerebro en eventos tales como la modulación 
de la plasticidad sináptica, en particular de uno de sus subtipos conocido como Long-term 
depression (LTD). IGF-1 también ha sido relacionado con la modulación de la transmisión 
sináptica, aunque se desconoce el alcance de su función en ese sentido. Además la seña-
lización de estos péptidos decae con el envejecimiento, afectando sin duda a los diferentes 
procesos que regulan.  En esta tesis hemos estudiado el efecto de la edad sobre la señaliza-
ción de insulina en hipocampo. Hemos podido determinar que la LTD dependiente de insuli-
na se encuentra afectada en el hipocampo de ratones viejos (20-24 meses) en comparación 
con el de adultos (7-12 meses). Los datos bioquímicos apuntan a un exceso de actividad de 
los receptores, y la alta activación posterior de la cascada de señalización a nivel citoplasmá-
tico, como posible explicación del déficit funcional de esta ruta. Ésto llevaría a la activación 
de una retroalimentación negativa de la señalización que causaría la posterior pérdida de 
sensibilidad de la vía. Es importante señalar que el fenotipo observado en el hipocampo no 
se corresponde con signos de pérdida de sensibilidad a insulina en el resto del organismo. 
A nivel de mecanismo, hemos podido observar que la disminución de colesterol que ocurre 
de forma normal en el hipocampo de ratones envejecidos juega un papel importante en la 
pérdida de sensibilidad a insulina. La recuperación de los niveles de colesterol propios de 
ratones adultos en hipocampo de ratones envejecidos, permite restaurar la actividad basal 
de la vía de señalización de la insulina e IGF-1, así como  una correcta LTD dependiente 
de insulina. Ensayos de microscopía confocal de FRET y experimentos de pérdida de fun-
ción de colesterol, nos han permitido demostrar que la pérdida de colesterol que ocurre en 
neuronas envejecidas lleva a una activación independiente de ligando de los receptores de 
insulina e IGF-1, causando los efectos posteriores de pérdida de sensibilidad observados. El 
tratamiento con Voriconazole, un inhibidor de la enzima CYP46A1, responsable de la pérdi-
da de colesterol en hipocampo con el envejecimiento, inhibe de forma efectiva la hiperacti-
vación de la señalización de insulina e IGF-1 y la presencia de marcas de insensibilidad en 
el substrato del receptor de insulina, permitiendo la recuperación de la señalización de la vía 
a niveles basales de un ratón adulto. Todos estos resultados ponen de manifiesto el papel 
relevante de los cambios lipídicos asociados al envejecimiento, como mecanismos efectores 
de la pérdida de sensibilidad a insulina vinculada a la edad en hipocampo.
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The insulin and IGF-1 signalling pathways are among the most widely studied routes 
in the organism. Their regulation is of vital importance in processes like metabolic homeosta-
sis or cell development and growth and therefore turned them into the object of exhaustive 
investigations, aiming at a deep understanding of the different processes they regulate in the 
different tissues of the organism. However, the intimate mechanisms by which the functions 
controlled by these peptides are not optimal in certain conditions remain incompletely ad-
dressed. In the brain, in addition to a body homeostasis role, a panoply of results indicate that 
insulin plays a role in cognition, mediated through its capacity to induce a synaptic plasticity 
event known as long-term depression (LTD). To a lesser extend, IGF-1 has also been related 
with synaptic transmission and modulation. In addition, the signalling power elicited by these 
peptides decreases with ageing, thus affecting the different processes they regulate. In this 
thesis we studied the effect of age on hippocampal insulin signalling. We determined that 
Insulin-LTD is impaired in the hippocampus of old mice (20-24 month-old) in comparison 
with adult mice (7-12 month-old). Biochemical data suggest that the functional deficit might 
be explained by an over-activity of the receptors leading to increased phosphorylation of the 
cytoplasmic effectors downstream, in turn triggering a negative signalling feedback resulting 
in pathway desensitisation. Importantly, the hippocampus phenotype is not accompanied by 
signs of abnormal body insulin sensitivity. Mechanistically, we observed that the mild reduc-
tion of cholesterol that normally occurs in the hippocampus of aged mice plays an impor-
tant role in the desensitisation of the pathway in this brain structure. Restoring hippocampal 
cholesterol levels in old mice to the values of adult mice allows the restoration of the basal 
activity of the insulin/IGF-1 signalling and a proper Insulin-LTD. Through FRET imaging and 
cholesterol loss of function experiments we demonstrate that the cholesterol loss occurring 
in old neurons leads to ligand-independent activation of the IR and the IGF-1R, consequently 
driving the posterior desensitising effects observed. The treatment with Voriconazole, an in-
hibitor of the CYP46A1 enzyme, responsible for the cholesterol loss in old mice hippocam-
pus, effectively avoids the hyper-activation of the IR/IGF-1R signalling and the presence of 
insulin desensitisation marks on the IR substrate, allowing the return of the pathway to an 
adult basal state. All together these results put age-associated changes in lipid content at a 
most upstream mechanism of age-associated hippocampal insulin desensitisation.
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The ageing process is defined as the time-dependent decline of biological properties 
that affects all organisms, impairing physical and cognitive functions. Despite it is not a dis-
ease by itself, ageing is a pro-morbid state that predisposes the organism to severe patholo-
gies, including cancer and neurodegenerative disorders.  Considering that in the next 30-40 
years the number of people over 60 years old will have doubled, elucidating the mechanisms 
of the different processes that drive ageing appears an important issue in the biomedical 
field. Nowadays, there is consensus about the different features of the ageing process, con-
stituting what are now known as the “Hallmarks of ageing” (López-Otín et al., 2013). These 
are: Genomic instability (mainly represented by DNA damage), telomere attrition, epigenetic 
alterations (that modify gene expression patterns), loss of proteostasis (affecting proteins’ 
folding, function and degradation), impaired nutrient sensing (altering principally insulin/IGF-
1 signalling), mitochondrial dysfunction, cellular senescence, stem cell exhaustion and al-
tered intercellular communication comprise the main characteristics of ageing (López-Otín et 
al., 2013). Several of the events that lead to the ageing phenotype are regular processes that 
occur physiologically in the cells in the course of every step in life, from early development to 
maturity (inflammatory/anti-inflammatory response or cellular senescence), however differ-
ent defects and cellular insults that accumulate in time could turn these cell responses into 
deleterious effects that finally drive the functional decay of the old. Likewise the exacerbated 
expression of some of these normal ageing characteristics has been linked to the occurrence 
of degenerative diseases (e.g. macular degeneration, Alzheimer’s disease).
As the rest of tissues in the organism, the brain also manifests the same ageing 
hallmarks, though adapted to its particular properties; namely that neurons, key cells in the 
cognitive and motor functions, become permanently arrested in the G0 phase of the cell cycle 
in the early stages of life, and thus must remain alive for the entire lifespan of the individual 
in order to guarantee proper communication. As neuron-neuron and neuron-target cell com-
munication reveals essential in brain nature, the incapacity of neurons to undergo replace-
ment makes these cells especially vulnerable to the effects of time. Thus, in the ageing brain 
synaptic loss and synaptic plasticity impairments are the main characteristics, more than the 
loss of neurons. This phenotype is indicative that synaptic function and not survival function 
is the main target of the ageing process in the brain. On the other hand, neuronal death is 
representative of pathological states like Alzheimer’s or Parkinson’s disease (Morrison et al., 
2012). 
Numerous brain structures participate in the cognitive process, both subcortical (the 
hippocampus, cerebellum, amygdala and basal ganglia) and cortical (frontal, parietal, oc-
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cipital and temporal lobes) structures. Thus, cognitive decay in the old must involve com-
munication deficits at all these levels. The most comprehensively studied of these structures 
is the hippocampus, which plays an active role in memory storage and the formation of new 
memories.  We will summarise in this introduction the principal signalling events that charac-
terise the synaptic functions in the hippocampus and how a reduced insulin/IGF-1 signalling, 
a constitutive defect in the old organism (Fontana et al., 2010; Mattison et al., 2012), could 
lead to cognitive deficits of the old. In addition, we will refer to the changes in brain cholesterol 
metabolism that occur during ageing, which we envision may be an upstream determinant of 
synaptic and insulin signalling defects of the old. 
1. Synaptic plasticity
One of the most interesting and important properties of the mammalian brain is its 
capacity to incorporate and retain external signals and experiences, in what is usually known 
as learning and memory processes. In its simplest form, learning and memory imply the 
transformation by neurons of incoming chemical signals into electrical currents, which are 
then integrated into neural circuits. The capacity of modifying these neural circuits, modulat-
ing, consolidating or removing them, to finally generate thoughts, feelings, memories and 
behaviours, is known as synaptic plasticity. More technically, synaptic plasticity comprises 
the modulation of strength and efficiency of the electric signals in synapses already estab-
lished.  The modifications of electric signals in synapses refer to any process that enhances 
or depresses them and lasts in time, allowing these processes to generate signalling pat-
terns that induce a change sufficient to create a new knowledge (learning) that can persist, 
as for example long-term memories. These alterations occur at the molecular and structural 
level both locally (at the synapse and peri-synaptic space) but also distantly, in the cell body 
and the nucleus, being different signalling pathways implicated. In these processes not only 
neuronal (synaptic) terminals participate but also the surrounding astrocytes (see Navarrete 
et al., 2012; Perea et al., 2014). 
The two best-characterised cellular processes underlying synaptic plasticity are long-
term potentiation (LTP), referring to the persistent increase in synaptic strength following high 
frequency stimulation, and Long-term depression (LTD), an activity-dependent reduction in 
synaptic strength following a long patterned stimulus. In addition to patterned stimuli to elicit 
LTP and LTD, there are other means to induce them, each with particular characteristics (Citri 
et al., 2008). Here we will summarise the pharmacological (NMDA-dependent) form of LTP 
and LTD and the specific subtype that will be studied in this thesis:  Insulin-LTD. 
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1.1  NMDAR dependent long-term potentiation
Initially observed in the CA1 region of the hippocampus, LTP is a kind of synaptic plas-
ticity triggered by activation of N-Methyl-D-aspartate receptors (NMDARs), and influenced 
by posterior modulation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors 
(AMPARs) (Martin et al., 2000). These receptors are ionotropic glutamate receptors present 
in the postsynaptic region of the synapse (Figure I1). NMDARs are permeable to Ca2+ and 
Na+ and their activation following the release from presynaptic terminals of the neurotransmit-
ter glutamate, which binds NMDARs (Nicoll et al., 1988), leads to the opening of the channels 
and membrane depolarisation. This initial depolarisation is propagated, in the plane of the 
membrane towards the cell body, to sub-synaptic domains to regulate receptor density at the 
plasma membrane, and towards the nucleus for the regulation of gene expression. During 
basal synaptic activity AMPARs provide most of the inward current, while NMDARs remain 
blocked by extracellular Mg2+ at negative membrane potentials (Mayer et al., 1984). A strong 
depolarisation is needed to unblock NMDARs channels, allowing an important inward current 
of Ca2+ that is required to reach the threshold for activating the signals necessary for achiev-
ing the receptor number change needed for LTP (Malenka, 1991). 
Once NMDARs channels are opened and Ca2+ enters the cell, different biochemical 
changes occur. The most relevant is the activation by autophosphorylation of the calcium/
calmodulin-dependent protein kinase II (CaMKII), an essential step for LTP (Malinow et al., 
1989; Pettit et al., 1994; Giese et al., 1998). Other kinases are also activated as result of the 
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Figure I1. Long-term potentiation processes. 
The figure represents the main LTP molecular pro-
cesses. Initial inward Ca2+ currents through NM-
DARs channels activate CaMKII and other kinases. 
This activation leads to biosynthesis of new proteins 
and modification in pre-existing scaffolding proteins, 
channels and regulatory proteins. All these events 
cause an increase in AMPARs delivery to the mem-
brane and their attachment to the postsynaptic den-
sity, favouring an intensification of synaptic signal-
ling, and thus promoting the maintenance of the LTP 
in time. Adapted from Derkach et al., 2007.
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initial triggering and contribute to LTP. Thus, via PKA activity the activation of inhibitor 1 oc-
curs, which inhibits protein phosphatase 1 (PP1) avoiding PP1-mediated dephosphorylation 
of CaMKII  (Makhinson et al., 1999). PKC or MAPK/Erk (Erk) have also been described to be 
important for later maintenance of LTP (Thomas et al., 2004; Serrano et al., 2005). However, 
the decisive event in LTP is the increase in AMPAR trafficking and insertion in the plasma 
membrane by the activation of these kinases (Derkach et al., 2007): CaMKII-mediated phos-
phorylation of scaffolding proteins to favour receptor insertion (Tomita et al., 2005) and PKA 
and PKC inducing AMPARs phosphorylation (Esteban et al., 2003; Boehm et al., 2006). LTP 
maintenance requires receptor insertion at the peri-synaptic membrane followed by lateral 
diffusion to the postsynaptic density (PSD). This is an area located in the postsynaptic termi-
nal, composed by multiple elements (some of the best characterised are PSD95, Stargazin, 
MAGUK protein family) that in the end determine the proper architecture and function of the 
synapse, including the insertion and retention of AMPARs and as consequence the sustain-
ing of the signal (Citri et al., 2008). In addition to AMPA receptor insertion, the persistence in 
time of LTP also relays in changes in dendritic spine´s architecture (Lüscher et al., 2000), and 
in local dendritic protein synthesis (Sutton et al., 2006) that would provide with components 
for the long-term maintenance of synaptic strength, in what is called late-phase of LTP.
1.2  NMDAR dependent long-term depression
Conversely to LTP, LTD is based on the weakening of the synaptic signals (Dudek et 
al., 1992). LTD discovery settled the theory that encoding of learning and memories in the 
brain relies on the modulation and distribution of synaptic weights in complex neural circuits 
(Mulkey et al., 1992) and not only in enhancer signals. As LTP, LTD depends on an initial 
activation of NMDARs, thus requiring an inward Ca2+ current. The main difference consists in 
the strength of the stimulation, which is weaker in LTD. However it must be enough for par-
tially relieving the Mg2+ block of NMDARs (Selig et al., 1995). Once the entry of Ca2+ is initi-
ated, the signalling cascade differs from LTP (Figure I2). If kinases were the main figures in 
LTP, phosphatases gain relevance in LTD.  A slight (compared to LTP) Ca2+ entry leads to 
calcium/calmodulin-dependent activation of the phosphatase calcineurin, also known as pro-
tein phosphatase 2B (PP2B), different from the effect of larger amounts of Ca2+ which result 
in the activation of CaMKII and LTP (Winder et al., 2001). Once activated, PP2B inhibits the 
protein inhibitor 1 through its dephosphorylation, thus avoiding PP1 repression and facilitat-
ing CaMKII dephosphorylation and inhibition (Lisman et al., 1989; Strack et al., 1997). In 
addition, other phosphatases like PP1 and protein phosphatase 2A (PP2A) become active 
further guaranteeing the achievement of LTD (Mulkey et al., 1993). All in all, with phos-
phatases activation during LTD, not only CaMKII but also other kinases involved in LTP such 
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as PKA or PKC become dephosphorylated (Lee et al., 2000) and inactivated. Likewise, 
dephosphorylation also affects the AMPARs residues that potentiate their conductance (Lee 
et al., 2000). This situation, together with the activation and inhibition of different proteins of 
the postsynaptic density or proteins implicated in lateral diffusion and architecture of the cell 
(Carroll et al., 2001), finally lead to the dissociation of AMPARs from the postsynaptic density 
and their endocytosis, in the end producing a weakening in synaptic strength. 
Figure I2. Long-term depres-
sion processes.
The image shows the main LTD 
molecular processes. Lower ini-
tial Ca2+ currents activate PP2B 
instead of CaMKII. This situation 
leads to the activation of differ-
ent phosphatases (PP1, PP2A) 
that inhibit the proteins that nor-
mally become active upon LTP. 
Phosphatases signalling is also 
driving modifications in scaffold-
ing proteins of the postsynaptic 
density that allow AMPARs to detached and be laterally mobilised heading to its endocytosis. Other proteins that 
were inactive under LTP signalling, like Gsk3β, are dephosphorylated and activated by phosphatases, enhancing 
AMPARs endocytosis and thus allowing signalling depression. Adapted from Collingrindge et al., 2010. 
Although the role of phosphatases seems predominant in LTD, several kinases be-
come active in this signalling as well and develop essential processes for the achievement 
of the synaptic depression. This is the case of proteins like cyclin-dependent kinase 5 (Cdk5) 
(Ohshima et al., 2005), p38 (Zhu et al., 2002) or Gsk3β. Gsk3β in particular has revealed 
as an important character for AMPARs endocytosis, being inhibited by Akt phosphorylation 
under LTP, and activated by PP1 dephosphorylation when LTD is initiated. Its blockage pre-
vents LTD induction (Peineau et al., 2007), representing a mechanism through which a syn-
aptic plasticity type impedes the other. Finally LTD is also maintained in time by means of 
changes in spine morphology (Zhou et al., 2004) and protein synthesis (Pfeiffer et al., 2006). 
1.3  Non-NMDA synaptic plasticity: the role of insulin 
In the mammalian brain, different classes of long-term potentiation and long-term de-
pression events take place, being enhancement or decline determined by the type of trigger-
ing stimulus, its intensity, presence of other stimuli, age, metabolic and stress background, 
all in all defining the different learning and memory experiences (Citri et al., 2008). Numerous 
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works indicate that insulin contributes to these changes. Thus, the observation of high con-
centrations of insulin receptor in the hippocampus, one of the brain structures with a crucial 
function in spatial learning and memory, was one of the first evidences supporting a role of 
this peptide in learning and memory (Wickelgren, 1998; Sonntag et al., 2005). This notion 
was later confirmed by a number of functional studies in rodents, showing that central insulin 
is involved in cognitive processes such as attention and executive functioning (Zhao et al., 
1999; Kern et al., 2001). Moreover, also in humans this role found support, especially from 
the works that showed that the direct application of insulin to the central nervous system 
(CNS) was an effective mean to reduce cognitive decline with age and also in Alzheimer’s 
disease (AD), and to also improve memory in young adults (Benedict et al., 2007; Freiherr 
et al., 2013). Mechanistically, these functional observations were supported by a number of 
recent evidences, among which are worth mentioning those that showed that insulin contrib-
utes, as co-adjuvant and even directly, to LTP and LTD (Van Der Heide et al., 2005; Martin 
et al., 2012; Blázquez et al., 2014). Before getting into the details of how brain insulin con-
tributes to synaptic plasticity, in the following sections we will summarise some key features 
of insulin signalling in general, both in the control of body homeostasis and in brain function. 
2. Insulin and IGF-1 signalling
Insulin and insulin-like growth factor-1 (IGF-1) are some of the peptides/hormones 
more extensively studied in molecular biology, exerting their functions along all tissues and 
cells. In addition to its specific role in the regulation of energetic homeostasis of all body 
cells, insulin is also implicated in cell division and development (Blázquez et al., 2014). IGF-1 
signalling has been mainly attributed a mitogenic role, with important functions in cell division 
and differentiation, taking relevance in cell maintenance, survival and tissue repair (Fernan-
dez et al., 2012).  In the brain, the best-studied role of insulin is on the control of food intake 
and satiety although lately both peptides have been attributed an important role in neuronal 
signalling and synaptic plasticity (Huang et al., 2004). Importantly, they have also been linked 
with organismal ageing, with age-associated signalling down-regulation being considered as 
a physiological response to ageing in order to increase lifespan. In the following sections we 
will summarise insulin and IGF-1 signalling pathways and their roles in the CNS.
2.1  Insulin and IGF-1 mechanisms of action
Insulin and IGF-1 function require binding to their respective receptors. Insulin recep-
tor (IR) and IGF-1 receptor (IGF-1R) belong to the receptor tyrosine kinase (RTK) family. 
Their structures are very similar and they share downstream signalling proteins, often acting 
cooperatively (Fernandez et al., 2012). The fact that both pathways are so intimately related 
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indicates that alterations in one route could influence on the other’s performance (Yakar et 
al., 2001; Moloney et al., 2010). Both types of receptors are formed by two α-subunits (extra-
cellular domain), each of which is bound by disulphide bonds to a β-subunit (transmembrane 
and cytosolic domains), forming αβ homodimers (O’Neill, et al., 2012). Although each recep-
tor can bind either peptide (i.e. IR can bind IGF-1 and vice-versa) the affinity is far higher for 
its own ligand. Moreover the α-β dimers can dimerise with subunits from the other type of 
receptor, giving rise to hybrid receptors that can bind both peptides, with preference for IGF-
1 rather than insulin (Pandini et al., 2002). 
Figure I3. Insulin/IGF-1 recep-
tors and signalling cascades. 
The picture depicts a simplified 
version of insulin/IGF-1 intracel-
lular signalling pathways, using 
IR cascade as general exam-
ple. IR and IGF-1R are highly 
homologous tyrosine kinase 
receptors. They can form hybrid 
receptors (HR) and bind each 
other ligand with lower affinity. 
The ligand induces cytosolic-tail 
auto- phosphorylation activat-
ing downstream proteins like 
IRS, SHC, Gab-1 or Cbl, which 
act as docking sites for different 
molecular effectors. This signal-
ling activates two of the main 
pathways for cell growth and survival: PI3K/Akt and MAPK/Erk pathways. Adapted from Zick et al., 2001.
To a large extent, ligand-receptor binding for both peptides elicits similar downstream 
signalling events (Figure I3). Ligand binding to the extracellular domain induces a structural 
modification in the transmembrane-region that drives this domain approximation and cyto-
solic-domain approximation and autophosphorylation at tyrosine residues, in turn triggering 
the phosphorylation of tyrosine residues in downstream effectors (Hubbard et al., 1994; Ta-
guchi et al., 2008; Kavran et al., 2014). These belong to two main pathways: PI3K and Erk. 
PI3K activation occurs by the docking to insulin receptor substrate scaffolding proteins (IRS 
1 to 4) following their activation by IR/IGF-1R phosphorylation. Erk is also activated after IR/
IGF-1R phosphorylation though through adaptors like Shc/Grb2 or Gab-1/Shp2 (Zick, 2001). 
In general terms, PI3K pathway activation by insulin/IGF-1 is more related to cell survival 
and metabolic regulation and Erk activation to mitogenic stimuli, survival and differentiation. 
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Likewise IGF-1R has been detected in the nucleus (Sehat et al., 2010), where it is thought 
to affect gene transcription directly. This last fact and the different receptors’ spatial and 
temporal expression patterns, transcriptional regulation and cellular compartmentalisation, 
could explain the existence of different functions for these receptors despite having the same 
downstream signalling pathway. 
Different control mechanisms have evolved to regulate the intensity and duration of 
the signals elicited by ligand binding, enhancing or attenuating them according to cell require-
ments. The IRS and Shc proteins are docking proteins playing a key role in propagating in-
sulin/IGF-1 signalling (Paz et al., 1997; Zick et al., 2001). These proteins contain a phospho-
tyrosine binding-domain (PTB-domain) which binds to the NPXpY motif in the insulin/IGF-1 
receptor. The subsequent phosphorylation on IRS creates binding sites for the SH2 domains 
of multiple signalling proteins, responsible for the recruitment and activation of the intracellu-
lar PI3K/Akt and MAPK/Erk biochemical pathways. Some differences exist however between 
IRS and Shc binding. The PTB domains of Shc and IRS both recognise autophosphorylation 
sites in RTKs but show distinct abilities to bind to different RTKs (Eck et al., 1996), such as 
the TrkA nerve growth factor receptor and the insulin receptor. Some studies suggest that 
subtle differences in the types of residues N-terminal to the NPXpY motif may determine the 
affinity with which phosphopeptide ligands are recognised by the Shc and IRS PTB domains. 
In vitro experiments have shown that, unlike IRS-1, the Shc PTB domain binds poorly to the 
IR beta subunit, owing to its low affinity for the NPXpY autophosphorylation site at Tyr 960 
(Van Der Geer et al., 1996) As a consequence, Shc does not bind stably to the activated IR 
in certain cells. This type of mechanism may explain the different trajectories of insulin and 
IGF-1 signalling in different cells, to direct signalling more or less towards the PI3K or MAPK 
cascades.
Signalling termination occurs upon the activation of particular proteins downstream in 
the pathway, however unrelated proteins are also able to drive it, like protein tyrosine phos-
phatases (PTPs) that can dephosphorylate the receptor or the downstream activated pro-
teins, thus inactivating them (Elchebly et al., 1999). In either case, the main physiological 
termination event conforms a negative feedback that allows the reduction of the signalling 
once the functions are accomplished (e.g. when blood insulin or glucose levels start to de-
crease). One of the stronger manners to attenuate IR/IGF-1R signalling is through Serine/
Threonine (Ser/Thr) phosphorylation on the IRS adaptors. There are several Ser/Thr resi-
dues in the IRS that could be considered as regulatory marks, enabling multiple control levels 
in a pathway that needs a complex and tight regulation. These marks usually disrupt the in-
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sulin/IGF-1 activation signalling at IRS level (Zick et al., 2001). 
Negative phosphorylation of IRSs is largely due to mTOR, p70S6K and PKC, down-
stream of PI3K/Akt pathway (Liu et al., 2001; Yuan, 2001). Negative Ser307, Ser616 or 
Ser632 on IRS-1 are the consequence of the activity of these kinases in rodents (also in the 
homologous residues in humans), being p70S6K a strong regulator of Ser307 and Ser632 
phosphorylation (Shah et al., 2004; Um et al., 2004). Other proteins like Jnk could also per-
form some of these regulatory marks, being Ser307 linked with this and other pro-inflamma-
tory proteins like IKKβ (Kanety et al., 1995; Aguirre et al., 2000; Yuan et al., 2001; Figure I4). 
The aberrant activation of all these kinases under certain pathological or stress conditions, 
like oxidative stress or chronic inflammation, leads to a permanent desensitised state called 
insulin/IGF-1 resistance, that impairs ligand signalling contributing to the development of dif-
ferent diseases (obesity, Type 2 diabetes, AD, etc.).
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Figure I4. IRS protein-mediated control feedbacks. 
The image shows the different control feedbacks mediated by IRS proteins phosphorylation. Akt/PKB ex-
erts a positive regulation by IRS serine phosphorylation, protecting IRS proteins from phosphatases action. 
mTOR, p70S6K and PKC/IKKβ regulate the physiological negative feedback of the pathway, allowing a 
correct performance of the IR/IGF-1R signalling and avoiding deleterious over-activating effects. Aberrant 
signalling, chronic inflammation and other altered stimuli cause a pathological negative feedback that leads 
to an insulin resistance state and disease (Type 2 diabetes mellitus, AD...). Adapted from Zick et al., 2001.
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2.2  Insulin and IGF-1 functions
2.2.1  Insulin physiological roles:
The main function of insulin in peripheral organs is the maintenance of glucose homeo-
stasis, contributing to glucose uptake in almost all the tissues and with special importance 
in those in charge of nutrients storage like liver, adipose tissue and muscle. Briefly, insulin is 
synthesised in the β cells of the pancreatic islets of Langerhans and stored in vesicles until 
release. Following food intake, glucose enters β cells freely by GLUT-2 (glucose transporter 
2) channels, and its degradation generates ATP. The increment in cellular ATP levels induces 
K+-ATP channels closure, resulting in depolarisation of the cell and activation of voltage de-
pendent Ca2+-channels. Inward Ca2+ leads to vesicle exocytosis and insulin release (Wilcox, 
2005). Different factors could influence β cells depolarisation and insulin secretion. Signals 
from hypothalamus (cholinergic stimulating, adrenergic inhibiting) (Wilcox, 2005), incretin 
hormones from the gut (like GLP-1 or GIP both stimulating) (Drucker et al., 2006) and amino 
acids or fatty acids (both activating) could influence insulin secretion. Insulin-receptor as-
sociation favours glucose transport, mainly through GLUT-4 insertion at the cell membrane, 
allowing glucose to entry. Likewise, insulin triggers glycogen synthesis in liver and muscle, 
gluconeogenesis inhibition in liver, fatty acid and cholesterol synthesis induction and lipolysis 
inhibition in adipose tissue. All in all, insulin´s principal role is a shift from catabolic to anabolic 
processes, required for cell growth, differentiation and energetic homeostasis effects in differ-
ent tissues (Wilcox, 2005).
2.2.2  Insulin in the brain:
During years, the brain was considered an insulin-insensitive organ, due to absence 
of insulin regulation for glucose uptake. However, we now know that insulin performs other 
functions in the brain, like the body’s glucose homeostasis and feeding behaviour control, 
neuronal development and learning and memory. In order to satisfy the demand of glucose 
brain cells utilise specific transporters independently from insulin action: GLUT-1 (endothelial 
cells and astrocytes), GLUT-2 (neurons in the hypothalamus), GLUT-3 (neurons of cerebel-
lum, cortex, striatum and hippocampus, observed also in glial and endothelial cells), GLUT-4 
(olfactory bulb, hippocampus, hypothalamus and cortex at low levels, slightly regulated by 
insulin) and GLUT-8 (glucose internal release in neurons). These transporters ensure glu-
cose supply for the CNS, completely essential for its function, thus enabling insulin to develop 
other functions (Gould et al., 1992; Piroli et al., 2002; Talbot et al., 2012; Blázquez et al., 
2014). Brain insulin comes from different sources. On the one hand it reaches the brain from 
the plasma through the blood-brain barrier (BBB), a structure that isolates the cerebrospinal 
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fluid (CSF) of the circulating blood, through a saturable transport process (Miller et al., 1994). 
It was also proposed that insulin could also access CNS via some regions like the hypothala-
mus where the BBB shows a laxer conformation (Kleinridders et al., 2013). The third source 
of brain insulin is by local synthesis. Although this possibility is still under debate, neurons not 
only synthesise insulin but also release it under certain stimuli like depolarising signals (Wei 
et al., 1990). Nevertheless the rate of insulin synthesis is lower in brain than in the periphery 
(Lee et al., 2016). 
Figure I5. Insulin regulation in the hypothalamus.
 The picture shows the regulation of food intake driven 
by insulin in the hypothalamus. Insulin exerts its effects 
in orexigenic and anorexigenic neurons of the hypotha-
lamic arcuate nucleus (ARC). It induces the downregu-
lation of neuropeptide Y (NPY) and agouti-related pep-
tide (AgRP) synthesis, two peptides that avoid satiating 
signals, together with hyperpolarisation that blocks the 
orexigenic neurons signalling to the paraventricular 
nucleus (PVN). Both events abrogate the food intake 
stimulation.  At the same time insulin induces the tran-
scription of proopiomelanocortin (POMC) and cocaine 
and amphetamine related-transcript (CaRT) in anorexi-
genic neurons. These peptides induce the synthesis of 
α-melanocyte-stimulating hormone (α-MSH) that acts on melanin-concentrating hormone (MCH) neurons in the 
PVN of the hypothalamus leading to signals that reduce food intake. Adapted from Kleinridders et al., 2014.
As mentioned, insulin exerts different functions in the brain, many of which are region-
specific. Thus, in the hypothalamus, insulin seems to be mainly involved in the control of 
feeding behaviour and energy homeostasis. In this structure, arcuate nucleus (ARC) neu-
rons sense blood insulin levels and produce diverse responses: orexigenic neurons express-
ing peptides like neuropeptide Y (NPY) or agouti-related peptide (AgRP) favour food intake 
whereas anorexigenic neurons expressing peptides like proopiomelanocortin (POMC) and 
cocaine and amphetamine related-transcript (CaRT) decrease food intake (Kleinridders et 
al., 2014). The insulin signalling induces in orexigenic neurons the reduction of both NPY and 
ArRP synthesis thus decreasing food intake stimulating signals. Simultaneously insulin leads 
to K+-ATP dependent channels opening in orexigenic neurons, causing the hyperpolarisation 
of the cells (Figure I5). This hyperpolarised status blocks their capacity to transmit signals 
to neurons in the paraventricular nucleus (PVN) where finally stimuli for food intake are trig-
gered or not (Spanswick et al., 2000; Plum et al., 2005). At the same time insulin induces 
synthesis in anorexigenic neurons of POMC and CaRT, leading to α-melanocyte-stimulating 
hormone (α-MSH) production (Benoit et al., 2002; Steculorum et al., 2014). This hormone has 
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its receptors MC4R in the PVN neurons, driving their activation and allowing them to signal 
for reducing food intake (Schwartz et al., 1996). Absence of insulin together with low levels of 
blood glucose triggers the opposite signalling, leading to food intake. It is considered that the 
obesity observed in pathologic situations like insulin resistance may be in part explained by 
the disruption of the orexigenic-anorexigenic signalling cascades (Kleinridders et al., 2009). 
Outside the hypothalamus, insulin´s role has been linked to different steps during 
brain development and growth. Thus, early work demonstrated that IR number increases 
during early stage of development (Roger et al., 1980) and ulterior work proved that this is an 
important event during the process of cell generation and for differentiation. Recent work also 
demonstrated that insulin is important for the survival and maintenance of neural stem cells 
(Rhee et al., 2013). In addition to its role in differentiation, insulin was demonstrated to be 
a potent neuroprotective agent, acting against processes like oxidative stress, beta amyloid 
toxicity and apoptosis (Ryu et al., 1999; Rensink et al., 2004). Besides, insulin was shown 
to protect neurons against injury damages, e.g. the effects caused by ischemic lesions can 
be reduced by insulin administration (Shuaib et al., 1995). In the hippocampus, insulin was 
shown to regulate GABA receptor density in postsynaptic domains, thus modulating electric 
signalling (Wang et al., 2003). It was also shown to participate in the uptake of amino acids 
required for synthesis of neurotransmitters and, as early mentioned, to take part of synaptic 
plasticity events (described in detail below).
2.2.3  IGF-1 signalling roles:
IGF-1 peptide is involved in cell cycle, survival, development and differentiation all 
across the body. This peptide is produced mainly in the liver, however all cells in the brain 
can express it. In addition to local synthesis, this peptide can reach the brain from the blood 
through IGF-1R expressed at the BBB (Nishijima et al., 2010), which seems to show higher 
permeability to IGF-1 than to insulin. Another group of proteins, IGF binding proteins (IG-
FBPs), bind IGF-1 in the body and in the CNS regulating the bioavailability of the IGF-1 pep-
tide. This group of proteins allows IGF-1 to prolong its half-life and are involved in processes 
like transport from blood to the CSF through the BBB (Fernandez et al., 2012). 
Regarding its functions, IGF-1 is implicated mainly in cell growth and differentiation, 
being even linked with aberrant cell growth processes like tumour development (Le Coz et 
al., 2016). At the brain level, IGF-1 is especially important in the development of CNS, for 
both neuronal and glial cells. Consistently, lack of IGF-1 causes alterations in brain growth 
and severe functional defects (Liu et al., 2009). In the adult brain IGF-1 has also relevant 
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roles in cell survival, principally after brain injuries, e.g. ischemia (Walter et al., 1997; Beil-
harz et al., 1998). As insulin, IGF-1 also plays a role in neuronal plasticity, due to its capacity 
to induce synaptic responses like LTD in the cerebellum (Wang et al., 2000) and improving 
cognitive tasks. Additionally. IGF-1 was shown to play an essential role in the formation of 
new neurons in adult brain and contributing to the recovery of learning and memory tasks 
after lesions (Trejo et al., 2001). 
2.2.4  Insulin and synaptic plasticity:
Several studies demonstrated the importance of insulin and insulin-signalling on 
electrically induced long-term potentiation (LTP). For example, haploinsufficiency of the IR 
β-subunit (Nisticò et al., 2012) or disruption of downstream signalling steps like IRS-proteins 
were found to impair CA1-LTP in the hippocampus (Martin et al., 2012). On the same line, it 
was shown that insulin treatment prevents the impairment in hippocampal CA1-LTP induced 
by streptozotocin in a rat model of diabetes (Izumi et al., 2003). Moreover, other studies re-
ported that infusion of glucagon-like peptide 1 (GLP-1) and enzymatically stable analogues 
promote insulin sensitivity and to either enhance LTP under control conditions (Gault et al., 
2008) or to ameliorate the deficits in LTP seen in different animal models of diabetes (Lennox 
et al., 2014). Thus, insulin modulates or promotes hippocampal LTP.
In addition to the function of insulin on LTP, insulin has a core mechanistic role in 
long-term depression (LTD). Thus, the mere application of insulin was found to cause LTD in 
the hippocampus without the necessity of additional electrical stimulation (Man et al., 2000; 
Huang et al., 2004; Van Der Heide et al., 2005). According to these studies, hippocampal in-
sulin-induced LTD (Insulin-LTD) is (i) generated by an insulin-induced AMPAR-internalisation 
(Man et al., 2000; Ahmadian et al., 2004), (ii) depends on an increase of postsynaptic Ca2+ 
concentration which is fed by either Ca2+-influx via NMDA receptors, L-type voltage-activated 
Ca2+ channels and the release of Ca2+ from intracellular stores, respectively, (iii) the activation 
of the PI3K/Akt pathway and (iv) the rapamycin-sensitive local translation of dendritic  mRNA 
(Huang et al., 2004). Altogether, these changes drive local changes in the scaffolding and 
structural proteins at the PSD leading to AMPARs endocytosis. These are the major proper-
ties of this type of LTD. 
2.3  Insulin and IGF-1 in brain ageing and disease
One pathway that is coming more and more into focus as a regulator of cognitive de-
cline during ageing is the insulin/IGF-1 pathway. Clinical and preclinical studies revealed a 
reduction of insulin and IGF-1 receptors, their message and their function in the hippocampus 
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during pathological ageing (Frölich et al., 1998; Zaia et al., 2000; Zhao et al., 2004; Deak, 
et al., 2012; De Felice et al., 2014; Talbot et al., 2014; Chami et al., 2016). A similar down-
regulation of brain insulin receptor signalling reduction was found in animal models of ageing 
and AD, often accompanying peripheral metabolic deregulation in type 2 diabetes mellitus 
(T2DM) (Pedersen et al., 2004; Rowe et al., 2007; Stranahan et al., 2008; Zhao et al., 2008; 
McNay et al., 2011). It is currently thought that the reduced insulin signalling that occurs in 
this organ during pathological ageing may be due to mechanisms analogous to those that 
account for peripheral insulin resistance in T2DM (Ferreira et al., 2014). 
As we have previously mentioned, both insulin and IGF-1 peptides are important for 
cell growth and tissue development. Their receptors are widely expressed in rodents dur-
ing development. Insulin receptors are found in olfactory bulb, hypothalamus, sub-thalamic 
nucleus, sub-fornical organ, CA 1/2 pyramidal cell layer of the hippocampus, cerebellum, 
amygdala, and cerebral cortex (Unger et al., 1989). Likewise IGF-1R is expressed in cortex, 
hippocampus, cerebellum, hypothalamus, brainstern and spinal cord (Adamo et al., 1989, 
Fernandez et al., 2012). During normal ageing these patterns seem to change, however 
there is controversy whether there is a decline or not in these signalling pathways. Different 
publications have reported a decrease in mRNA transcription levels of insulin/IR and IGF-1/
IGF-1R pathways in rodents and in humans, in agreement with the works that reported de-
crease at the protein level (D’Costa et al., 1995; Frölich et al., 1998; Lee et al., 2014). Con-
trarily, other researchers showed lack of changes or even increased levels with age (Doré et 
al., 1997; Chung et al., 2002). Though it seems that the loss of activation of these receptors 
with normal ageing is more accepted (Fernandes et al., 2001; Poe et al., 2001), leading to a 
reduction in the capacity of these signalling cascades to become active upon stimuli. 
Moreover, in many instances insulin and IGF-1 resistance develop in parallel with con-
ditions associated to inflammation and oxidative stress that finally could drive a worsening in 
the normal ageing phenotype and the development of diseases like T2DM and AD. Numer-
ous evidences indicate that both pathologies are closely connected. Thus, it was observed 
that hyperinsulinemia and hyperglycaemia due to insulin resistance enhance neuritic plaques 
formation (Matsuzaki et al., 2010) and in turn such Aβ deposition reinforces brain insulin 
resistance through IR signalling reduction (Xie et al., 2002; Lee et al., 2009). Likewise situ-
ations of chronic inflammation, oxidative stress and insulin resistance linked to obesity and 
T2DM could favour Aβ deposition (Sheng et al., 2003; Nizari et al., 2016). Ultimately, Aβ and 
insulin are both substrates of insulin-degrading enzyme, and it was shown that Aβ degrada-
tion is impaired in T2DM hyperinsulinemia situations by the competitive blockage of the de-
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grading enzyme (Farris et al., 2003). Thus the association insulin resistance with pathological 
brain ageing is not only supported by different epidemiological studies in humans but also by 
biochemical cause-effect evidences in different experimental set-ups.  
In light of the above association, different treatments have emerged lately to compen-
sate this insulin/IGF-1 signalling impairment and ameliorate Alzheimer´s symptoms. Thera-
pies that stimulate insulin secretion or intranasal delivery of insulin/IGF-1 have been demon-
strated to decrease Aβ deposition in mice and humans  (Carro et al., 2002; Craft et al., 2012). 
Similarly, treatments in mice and humans with insulin sensitising agents like metformin or 
incretin analogue molecules have demonstrated to be effective in the treatment of insulin re-
sistance, reducing mild cognitive impairment (Hsu et al., 2011; McClean et al., 2011). On the 
other hand, numerous publications indicate that insulin/IGF-1 signalling reduction in different 
species is associated with longer lifespan, and better outcome of Alzheimer´s (Holzenberger 
et al., 2003; Van Heemst et al., 2005; Selman et al., 2008). Thus, it was shown that the partial 
ablation of IGF-1R in mice models for AD reversed its symptoms through decreasing soluble 
Aβ oligomers and reducing inflammation (Cohen et al., 2009). Hence, although all these 
data clearly indicate that the brain is, like any other organ, highly sensitive to insulin and 
IGF-1 signalling, we still do not know the intimate mechanisms involved in brain insulin/IGF-1 
signalling reduction with age, and even less how these affect brain pathological conditions 
associated with ageing like AD. In this regard, it appears important to mention the numer-
ous studies reporting that the membranes of erythrocytes, leukocytes and skeletal muscle 
cells of diabetics are rich in rigidity-promoting lipids, namely cholesterol, sphingomyelin and 
saturated fatty acids (Borkman et al., 1993; Ruiz-Gutierrez et al., 1993; Clifton et al., 1998; 
Bakan et al., 2006), suggesting that defective insulin signalling in diabetes might be due to 
a defective membrane organisation (i.e. due to reduced receptor clustering in rafts). The nu-
merous works showing changes in brain lipid composition with age (see Colin et al., 2016) 
could explain insulin signalling deficits in this organ as well. However interesting, these stud-
ies do not help to determine if lipidic changes determine pathology or they are (yet another) 
consequence of it. 
3. Cholesterol in the brain
Cholesterol is an essential component of eukaryotic membranes. Its particular com-
position and characteristics make it essential in plasma membrane dynamics, especially rel-
evant in the regulation of membrane fluidity, thickness and generation of sub-compartments 
(lipid rafts), with specific organisation and roles. The substantial role of cholesterol in the for-
mation of these sub-domains is particularly pivotal, as these sub-compartments act as scaf-
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folds for different and crucial signalling platforms, including insulin (Simons et al., 1997). Due 
to these singular characteristics, cholesterol has the capacity to influence ion channel perme-
ability, death-survival signalling, exo-endocytosis, gene expression and, especially relevant 
for an organ like the brain, synaptic vesicle release and neurotransmitter receptor fusion 
and internalisation (Maguire et al., 1989; Valenza et al., 2005 and 2015; Lippincott-Schwartz 
et al., 2010; Mailman et al., 2011 Levitan et al., 2014). Therefore, a significant alteration in 
cholesterol levels and homeostasis in brain cells will undoubtedly have deleterious conse-
quences. In fact, numerous works have linked brain cholesterol with cognitive defects in the 
normal old and with the occurrence of neurodegenerative features. Below, we will summarise 
the main features of cholesterol general homeostasis and functions in the brain, focusing 
then in its relationship with ageing and pathology.
3.1  Brain cholesterol 
3.1.1  General considerations:
Although the brain represents 2% of body mass, it contains 23% of the whole choles-
terol content. This clearly indicates the crucial importance of this lipid for brain organisation 
and function.  The greatest proportion of brain cholesterol is present in the myelin sheaths, 
an essential component for the propagation of action potentials along axons. The rest of the 
cholesterol in the brain is present in the plasma membrane and endo-membranes of other 
brain cells: neurons, astrocytes and microglia. Yet, due to their size, architectural complex-
ity and functional properties, it is thought that neurons are extremely sensitive to changes in 
cholesterol content. This is corroborated by the observation that the brain is the main affected 
organ in hereditary conditions of gene mutations in cholesterol synthesis/transport genes, 
despite their presence in all cells of the organism (reviewed in Martin et al., 2014a). Another 
peculiarity of brain cholesterol is that all cholesterol in the brain is the product of synthesis by 
brain cells, since the BBB blocks the entry of blood lipoprotein-cholesterol particles. There-
fore, the levels of cholesterol in the brain are not to be related with peripheral alterations 
(Björkhem et al., 2004).
3.1.2  Cholesterol synthesis:
The first step in cholesterol synthesis in all the tissues consists in the transformation 
of acetyl-CoA in 3-hydroxy-3-methylglutaryl-CoA by HMG-CoA synthase (Konrad, 1992). The 
reduction of this product through HMG-CoA reductase (HMG-CoAR) results in Mevalonate, a 
molecule that will be subject to a 19-step process of enzymatic reactions to finally yield cho-
lesterol (Berg et al., 2002). The initial steps in cholesterol synthesis take place in the endo-
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plasmic reticulum (ER), nevertheless it is not abundant in this organelle, where it represents 
a 1% of total cell cholesterol (Ikonen et al., 2008). Once synthesised it is delivered mainly to 
the plasma membrane, where it accounts for a 25% of total lipids. Other membranes rich in 
cholesterol are the endocytic recycling compartment and the Golgi apparatus, mostly en-
riched in the trans-Golgi compartment. The cholesterol level in the cell is precisely tuned by 
the SREBPS system. The SREBPs (sterols regulatory element-binding proteins) are mem-
brane-bound transcription factors settled in the ER. When these proteins sense a reduction 
in cholesterol they are delivered to the Golgi, where upon activation they translocate to the 
nucleus to regulate the transcription of cholesterol synthesis genes (HMG-CoAR) and lipo-
protein (cholesterol transporter molecules) receptor genes (LDLR) (Smith et al., 1988 and 
1990).
Figure I6. Cholesterol production in glial cells 
and delivery to neurons. 
The diagram shows how astrocytes (red) produce 
and deliver cholesterol to neurons, using lipopro-
teins like APOE. Enzymes like LCAT, that esteri-
fied cholesterol allowing it to enter the lipoprotein, 
could modify the cholesterol present in these li-
poproteins. The acquisition of lipoproteins by neu-
rons (blue) is mediated by receptors like LDLR 
and LRP1. Once inside the neurons cholesterol 
is released from endosome/lysosome system by 
NPC proteins that allow it to go to its destinations. 
The excess of cholesterol could be stored esteri-
fied by enzymes like SOAT1, expelled to CSF in li-
poproteins through transporters like ABCA1 or de-
graded to 24OHC by CYP46A1 enzyme. Adapted 
from Pfrieger et al., 2011.
Cholesterol synthesis varies among the different cell types of the brain and also in 
relation to time of development. Cholesterol synthesis is at high rate during brain postnatal 
development and significantly decreases with age (Quan et al., 2003; Thelen et al., 2006). 
Regarding synthesis rates in the different brain cells, oligodendrocytes produce their own 
cholesterol as so do astrocytes at all times. Neurons on the other hand are self-dependent 
at initial stages of development but once myelination is completed, in early life, they rely on 
astrocytes synthesis and delivery (Fünfschilling et al., 2007). It has been postulated that the 
astrocyte dependence is a way to spare energy to neurons, due to the high amounts of en-
ergy and resources that cholesterol synthesis requires (Mauch et al., 2001). The pathway of 
astrocyte-to-neuron cholesterol provision is schematised in Figure I6. In short, synthesised 
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cholesterol by astrocytes is stored in the form of esterified cholesterol. Upon secretory signal-
ling, astrocytes´ lipoproteins, APOE (apolipoprotein E, one of the most important), APOJ/CLU 
or APOD form high-density lipoproteins (HDL) with esterified cholesterol (at lower levels than 
the HDL particles in serum) and several cholesterol precursors, as desmosterol or lathoster-
ol, that then the neurons transform in cholesterol (DeMattos et al., 2001; Mutka et al., 2004). 
Cholesterol transfer to the particles is mediated by ATP binding cassette (ABC) transporters 
(Fukumoto et al., 2002; Tarr et al., 2008). These particles are secreted to the interstitial space 
by mechanisms similar to those employed by hepatocytes, i.e. assembly in the ER, transfer 
to the Golgi and secretion. 
Uptake of cholesterol lipoparticles by neurons is mediated by specific receptors that 
bind APOE and the other lipoproteins. The most important receptors in neurons are LRP1 
(mainly expressed in neurons) and LDLR (that can also be expressed in astrocytes) (Pfrieg-
er et al., 2011). Upon internalisation by receptor-mediated endocytosis, cholesterol follows 
the endosomal/lysosomal system, where it is released and delivered back to the plasma 
membrane or to internal organelles. One mechanism of release involves the NPC2 protein 
present in the lumen of late endosomes. This protein binds unesterified cholesterol from 
lipoproteins and transfers it to the NPC1 protein. This is a transmembrane protein with a 
sterol sensitive domain that mediates the exit of cholesterol from the endosomal/lysosomal 
system (Storch et al., 2009). Additionally to this mechanism, cholesterol taken up from as-
trocytes might be stored in its esterified form. This comes from the observation that neurons 
express the ACAT1/SOAT1 proteins, which have been involved in cholesterol esterification, 
(Sakashita et al., 2000). In addition to cholesterol uptake mechanisms, neurons possess a 
well-developed system for removing it. Despite there being studies that describe expression 
of ABC transporters in neurons, and the possibility of direct cholesterol excretion on APOA1 
or APOE-containing lipoproteins (Fukumoto et al. 2002), the most active pathway for choles-
terol removal in neurons is its conversion to 24S-hydroxycholesterol (24OHC) by the enzyme 
cholesterol 24-hydroxylase or CYP46A1 (Figure I7).
CYP46A1 is mainly expressed in different neurons in the brain and little in astrocytes 
(Ramirez et al., 2008). The 24OHC product generated by its action is able to translocate 
through the different lipophilic compartments in the brain, including the BBB, being the main 
mechanism by which the brain eliminates the excess of cholesterol. In addition, 24OHC re-
leased from neurons plays a fundamental role in the control of brain cholesterol content by 
means of its binding to LXR receptors in the astrocytes. Binding triggers the expression of 
proteins like APOE or ABCA1 implicated in the excretion of cholesterol (Wang et al., 2008) 
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thus synchronising the cholesterol status of neurons and astrocyte to assure that this essen-
tial lipid is maintained at appropriate levels. 
Figure I7. 24OHC effects on cholesterol 
homeostasis. 
The diagram indicates how 24OHC, product 
of cholesterol degradation, is released to the 
CSF for its elimination, or could be incorpo-
rated by astrocytes. 24OHC activates LXR 
receptors in astrocytes stimulating choles-
terol synthesis and delivery to neurons, thus 
controlling and regulating cholesterol home-
ostasis in the brain. Adapted from Björkhem 
et al., 2004.
3.2  Cholesterol in synaptic signalling
As previously mentioned, besides its important functions in membrane structural 
maintenance, cholesterol it is also implicated in the organisation of functional structures. 
Cholesterol is not homogeneously distributed in the membranes, appearing at higher levels 
in sub-domains known as lipid rafts that constitute by themselves functional entities with 
important relevance for cell signalling and trafficking (Simons et al., 1997). The formation 
of these specific structures allows the recruitment into signalling platforms of particular pro-
teins that on the one hand participate in downstream events and at the same time modulate 
the proper organisation of the rafts. Although not exclusively, lipid rafts are abundant at and 
around synapses, where they have been found to contribute to neurotransmission and also 
to receptor-mediated intracellular signalling (Cooper et al., 1984; Pfrieger et al., 2003; Oh et 
al., 2007; Chen et al., 2008). It is in this regard where the control of brain cholesterol levels 
throughout life acquires maximal relevance, as any content change, in more or in less, will 
certainly influence synapse function and, as a consequence, brain performance. 
3.2.1  Cholesterol in presynaptic terminals:
The release of neurotransmitters from presynaptic terminals is a crucial step for the 
correct transmission of neuronal signals. The neurotransmitters are molecules produced by 
neurons for spreading their electrical signalling. They are accumulated in vesicles that remain 
close to the plasma membrane ready to fuse with it under a signal and release their contain 
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to the intracellular space. In this releasing process the protein complex SNARE is crucial 
for accomplishing the fusion of the vesicles to the plasma membrane (Sollner et al., 1993; 
Takizawa et al., 1993). This process requires a perfect coordination between the different 
components of the plasma membrane, lipids and proteins. In this complex organisation, cho-
lesterol plays an important role and it is revealed as an essential element of the exocytosis 
structure. Different studies revealed the presence of high levels of cholesterol in presynaptic 
terminals and it was shown that the reduction of cholesterol causes a decrease in vesicle 
exocytosis (Mailman et al., 2011). The intrinsic negative curvature of cholesterol, a property 
required for vesicle merging process, could explain this situation (Jahn et al., 1999). It has 
also been described an association between SNARE complexes and lipid rafts (Lang et al., 
2001). Thus the alteration of cholesterol levels could lead to destabilisation of exocytosis pro-
tein complexes, affecting the capacity of the neurons to trigger the neurotransmitters release 
(Chamberlain et al., 2001). Likewise, different publications linked cholesterol with vesicle 
formation in neurons, reporting a relation between cholesterol levels and rate of vesicle gen-
eration (Hannah et al., 1999). Finally, other studies revealed that kinesin-mediated vesicle 
transport in the cell requires the presence of lipid rafts (Klopfenstein et al., 2002), which could 
also relate cholesterol with neurotransmitters delivery. 
3.2.2  Cholesterol in postsynaptic terminals:
Presynaptic structures find their counterparts in the so-called postsynaptic terminals. 
These regions contain the receptors to the different neurotransmitters that are produced and 
released by neurons, as well as other kind of receptors and ion channels also related with 
synaptic transmission. The particular organisation of the plasma membrane in lipid rafts, 
make them suitable to cluster and potentiate the activity of all these types of receptors and 
channels. This however does not imply that all receptors and channels are present in lipid 
rafts, but instead that lipid rafts serve as transient platforms facilitating receptor organisation, 
lateral diffusion and gathering in functional complexes finally favouring signal transference. 
In fact, some receptors and channels have been found in lipid rafts, as for example nicotinic 
acetylcholine receptors (AChRs), AMPA receptors, GABA receptors and also scaffolding pro-
teins that form part of these postsynaptic structures like PSD95 protein or glutamate-receptor 
interacting protein (GRIP) (Brückner et al., 1999; Brusés et al., 2001; Suzuki et al., 2001).
 
Again, as one of the main components of these lipid rafts, a change in cholesterol lev-
els in neurons leads to alterations in postsynaptic terminals. This is exemplified in the increase 
in glutamate receptor-mediated currents when cholesterol levels are increased (Mauch et al., 
2001). Another example is the increasing accumulation of AMPA receptors with cholesterol 
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reduction, due to their impaired lateral mobility and decreased endocytosis (Martin et al., 
2014b).  In addition to these direct effects in the regulation of pre and postsynaptic currents, 
cholesterol plays a role in the stability of the synapse through affecting the properties of adhe-
sion proteins present in synaptic and peri-synaptic lipid rafts (He et al., 2002; Leitinger et al., 
2002). Thus, neuronal membrane cholesterol controls critical aspects of synaptic transmis-
sion, at the level of channels and receptors but also at the architectural level. 
3.3  Cholesterol in Alzheimer’s disease and ageing
Cholesterol homeostasis in brain cells has been revealed a critic issue during lifes-
pan. As previously shown it has great importance for the correct maintenance of membranes 
structure and particularly in neurons is intimately linked with correct synaptic performance. 
Thereby it is easy to assume that cholesterol homeostasis deregulation in the CNS could 
cause or at least influence the cognitive process. In fact, there are numerous works showing 
that defects in brain cholesterol homeostasis play a critical role in the cognitive deficits of the 
old, but also in the development of neurodegenerative diseases, like Alzheimer´s disease 
(reviewed in Martín et al., 2014a). 
3.3.1  Alzheimer’s Disease:
A relationship between cholesterol with AD has been suggested by different types of 
data, including human retrospective studies, genetic association and direct biochemical ex-
perimentation in laboratory animals (reviewed in Martin et al., 2014a). Hypercholesterolemia 
is a major risk for AD, though the cause for it may relate to brain hypo-perfusion, inflamma-
tion, endothelial cell dysfunctions or blood-brain barrier breakdown rather than a reflection in 
the changes in cholesterol content (Altman et al., 2010; Vasilevko et al., 2010). As mentioned, 
high levels of blood cholesterol are related with insulin resistance, in turn affecting amyloid 
processing, among other alterations  (Kruit et al., 2010; Matsuzaki et al., 2010). Another 
mechanism by which high circulating cholesterol may favour AD is by the excess of cholester-
ol catabolic products, the oxysterols. Circulating oxysterols worsen the atherogenic process 
and induce vascular cells apoptosis (Poli et al., 2009). Yet the most conclusive data linking 
high cholesterol with AD is the inheritance of the ε4 allele of the ApoE gene. The presence of 
this allele is related to cardiovascular diseases and atherogenicity (Schmechel et al., 1993), 
and at the brain level with impaired cholesterol transport, reduced myelin formation and lower 
capacity to degrade beta amyloid peptide (Martin et al., 2014a). In light of the numerous 
observations that cholesterol levels are diminished in AD brains (see reviews by Martin et 
al., 2014a and by Colin et al., 2016) it appears reasonable to propose that brain cholesterol 
metabolism is a sensitive indicator of body homeostasis. The mechanisms by which the brain 
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reduces cholesterol content in the hypercholesterolemic background are not known, though 
they might have different origins; among others, impaired cholesterol uptake by neuronal 
cells (Beel et al., 2010), inhibition of cholesterol synthesis by amyloid beta peptide, modifica-
tion in lipid rafts (Evangelisti et al., 2014) or increased CYP46A1 activity leading to higher 
levels of degradation products and lower levels of cholesterol (Lütjohann et al., 2000). Hence, 
the association between high blood cholesterol with AD appears to be the consequence of 
a brain vascular response to hypercholesterolemia resulting, among other numerous conse-
quences, in changes in brain cholesterol homeostasis, with its obvious functional alterations. 
3.3.2  Ageing:
It has been previously reported that brain lipidic composition changes with age. In 
particular different groups have reported a cholesterol reduction, both in the human brain 
and in rodents (Svennerholm et al., 1994 and 1997; Martin et al., 2014a, Colin et al., 2016), 
being the hippocampus one of the regions affected. The mechanisms proposed to explain 
this loss are multiple: age-reduced synthesis, age-reduced astrocyte-neuron communication 
and age-increased levels of the cholesterol hydroxylating enzyme CYP46A1 (see Martin et 
al., 2014a). Changes in this enzyme seem to be particularly relevant for the age associated 
cholesterol deficit: i) its levels are regulated at the transcriptional level by oxidative metabo-
lites (Ohyama et al., 2006), a typical feature of aged cells, and ii) oxidative stress increases 
the enzyme’s mobilisation from internal reservoirs (the ER) to the plasma membrane (Sodero 
et al., 2012). Expectedly, age-associated cholesterol loss was correlated with several synap-
tic plasticity deficits of the old. Thus, it was reported that cholesterol loss impairs long-term 
depression (LTD) through altering NMDA receptors signalling, leading to impaired activation 
of the CaMKII-CREB/CBP and, by these means, decreased histone deacetylase 4 (HDAC4) 
displacement from repressed chromatin resulting in reduced transcription of early memory 
genes (Palomer et al., 2016a). It was also observed, that age-associated cholesterol loss 
is behind the upregulation of TrkB activation, in turn leading to upregulation of Akt signal-
ling and impaired AMPA receptors mobilisation and internalisation, both events required for 
LTD induction (Martin et al., 2014b). Furthermore, cholesterol loss was also shown to af-
fect long-term potentiation (LTP) by a mechanism that involves the detachment from plasma 
membrane of the protein MARKCS. The lower MARCKS levels in turn induce a reduction in 
PI(4,5)P2 levels leading to decrease PLCγ activity (Trovò et al., 2013). All in all, these data 
shed light into some of the mechanisms by which changes in cholesterol homeostasis with 
age could be partly responsible for the deficits in cognition that characterise this stage of life. 
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The insulin and IGF-1 signalling‘s functions and roles in the brain have been gaining 
interest lately due to their increasing importance in learning and memory events. Despite the 
numerous works showing the existence of insulin and IGF-1 signalling deficits with age and in 
pathological conditions like Alzheimer´s, and that these deficits are associated with cognitive 
decay, it is still missing a direct demonstration that age affects insulin/IGF-1 synaptic plastic-
ity functions. Hence, the objectives we have tackled during this thesis were:
1. To determine the effect of age on insulin-mediated synaptic plasticity.  
2. To determine the effect of age on the molecular mechanisms responsible for insu-
lin-mediated synaptic plasticity. 
3. To attempt to improve insulin/IGF-1 signalling in the old.
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1.  Human embryonic kidney (HEK) cells in culture
Hek 293T cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 10% Fetal Bovine Serum (FBS), 2 mM Glutamine, 100 IU/ml Penicillin and 100 
mg/ml Streptomycin (complete DMEM). Cells were incubated at 37ºC, humidity conditions 
and 5% CO2.  
2.  Primary hippocampal neurons 
Hippocampal neurons were extracted from Wistar rat embryos at embryonic day 18 
(E18) and seeded in culture conditions as previously described (Kaech et al. 2006). Briefly 
hippocampi were dissected into ice-cold Hank’s solution (Hank’s buffer salt solution (HBSS) 
Ca2+ and Mg2+ free, Gibco, Life Technologies Co.) with 7 mM HEPES and 0.45% glucose. We 
treated the hippocampi with 0.005% trypsin (Trypsin-EDTA 0.05%, Gibco, Life Technologies 
Co.) and kept them at 37ºC for 16 min. Tissue was washed three times with Hank’s solution 
and then dissociated in 5 ml of plating medium (Minimum Essential Medium (MEM) sup-
plemented with 10% horse serum and 20% glucose). Cells were counted using a Neubauer 
Chamber and plated into poly D-lysine 0.1% (Sigma-Aldrich) pre-coated dishes (250000 cells 
in a 6 cm culture dish).
Plating medium was replaced after 4 hours by neurobasal media supplemented with 
B27 and GlutaMAX (Gibco, Life Technologies Co.). After 7 days in vitro (DIV) medium was 
replaced by the same medium without GlutaMAX. We maintained the neurons in culture at 
37ºC, humidity conditions and 5%CO2, until they were fully mature at 15 DIV.
3.  Mouse hippocampal slices
Hippocampal slices were obtained from C57BL/6J mice, using 7-12 month-old mice 
as adult mice and 20-24 month-old mice as old mice. Hippocampi were extracted and placed 
in Dissection solution (10 mM D-glucose, 4 mM KCl, 26 mM NaHCO3, 233.7 mM sucrose, 
5 mM MgCl2, 1:1000 Phenol red) oxygen saturated with carbogen (95% O2 / 5% CO2), and 
sliced using an automatic tissue chopper (McIlwain Tissue Chopper, Standard Table, 220 V, 
Ted Pella Inc.) to obtain 400 µm hippocampal slices. Then slices were kept in artificial cer-
ebrospinal fluid (ACSF: 119 mM NaCl, 2.5 mM KCl, 1 mM NaH2PO4, 11 mM glucose, 1.2 mM 
MgCl2, 2.5 mM CaCl2, osmolarity adjusted to 290 Osm) oxygen saturated with carbogen for 
1 hour. Experiments were performed in ACSF oxygen saturated.
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4.  Drug treatments
Different drugs and compounds were prepared for hippocampal neurons and Hek 
293T cells treatment. Stock solutions of insulin-like growth factor-1 receptor β (IGF-1Rβ) and 
insulin receptor β (IRβ) inhibitor Osi-906 (50 mM Selleckchem ref.: S1091), IGF-1Rβ inhibitor 
PPP (10 mM Calbiochem ref.: 407247), p38 inhibitor PH797804 (10 mM Selleckchem ref.: 
S2726) and Jnk inhibitor SP600125 (50 mM Tocris ref.: 1496) were prepared in dimethyl 
sulfoxide (DMSO, Sigma-Aldrich). Stock solutions of Cholesterol oxidase (Choox, 500 IU/ml, 
Calbiochem ref.: 228250) and human peptide purified IGF-1 (13 µM, Stem Cell Technologies 
#78022) were prepared in Milli-Q water. 
Hippocampal neurons were treated with 1 µM Osi-906 (1 hour), 1 µM PPP (1 hour), 
2 µM PH797804 (1 hour) and 10 µM SP600125 (1 hour) prior to cholesterol removal with 10 
IU/ml Choox (30 min). Hek 293T cells were treated with 4 µM IGF-1 (25 min) and 40 IU/ml 
Choox (1h) before paraformaldehyde (PFA) fixation for FRET experiments (see below para-
graph 14). All treatments on hippocampal neurons or Hek 293T cells were performed at 37ºC. 
Experiments for cholesterol addition conducted in hippocampal slices were performed 
at 25ºC. Methyl-β-cyclodextrin-cholesterol (MβCD-Ch) solution was prepared freshly at use 
concentration in ACSF, containing 30 µM Cholesterol Water-soluble (Sigma-Aldrich ref.: 
C4951) and 5 µM Cholesterol (Sigma-Aldrich ref.: C3045). After hippocampal slices prepara-
tion and recovery (1 hour in ACSF oxygen saturated), hippocampal slices were treated with 
MβCD-Ch solution (1 hour) for cholesterol addition and collected for further processing. 
5.  Animal handling
Male C57BL/6J mice were used in this study:  adult 7-12 month-old and old 20-24 
month-old. All the animals were kept in the Centro de Biología Molecular Severo Ochoa’s 
(CBMSO) animal facility, with food and water available ad libitum. Animals were maintained 
in a temperature-controlled environment, following a 12-12 light-dark cycle beginning light at 
7 a.m. All the experiments were performed in accordance with European Union guidelines 
(2010/63/UE) regarding the use of laboratory animals.
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6.  Animal treatment
Voriconazole (from HangZhou Dayangchem Co., CAS No: 137234-62-9) was solubi-
lised using hydroxypropyl-β-cyclodextrin (Sigma-Aldrich ref.: H107): 15 g of hydroxypropyl-
β-cyclodextrin were dissolved in 100 ml of saline solution (0.9% NaCl) and heated to 80°C in 
a water bath with stirring. Then 1.5 g of Voriconazole were added to the cyclodextrin solution 
with stirring at 80°C until complete dissolution. This stock solution (15 mg Voriconazole/ml 
cyclodextrin/saline) was conserved at 4°C protected from light. On the first day of experi-
mentation, an aliquot of this solution was diluted in drinking water to a final concentration 
of 0.68 mg/ml Voriconazole. Considering that a mouse drinks 3 ml water per day, the dose 
corresponds to 2.04 mg/day. The average weight of a mouse is 34 g, resulting therefore in a 
dose 60 mg/kg body weight. Water with this concentration of Voriconazole was used as the 
hydration source in 20 month-old mice during 45 days. Vehicle 20 month-old mice received 
the same amount of hydroxypropyl-β-cyclodextrin than Voriconazole mice during 45 days. 
Bottles containing the Voriconazole or Vehicle water were changed weekly.
7.  Protein extracts processing
Protein extracts were obtained from cultured hippocampal neurons or hippocampi 
extracted from C57BL/6J mice and homogenised in RIPA buffer (20 mM Tris-HCl ph7.5, 150 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, phos-
phatase inhibitor cocktail 2 Sigma-Aldrich and protease inhibitor Complete Roche). Extracts 
for cholesterol measurements either from hippocampal neurons or from mice hippocampi 
were homogenised in MES buffer (25 mM 2-N-Morpholino ethanesulfonic salt pH7, 2 mM 
EDTA, phosphatase inhibitor cocktail 2 and protease inhibitor Complete). Protein concen-
tration was determined using the colorimetric assay BCA (Pierce ® BCA protein assay kit, 
Thermo Fisher Scientific) 
8.  Electrophoresis and protein detection by Western Blot
Protein extracts were boiled at 99ºC for 5 min. in Laemmli Buffer (125mM Tris pH 6.8, 
1% SDS, 3.48% glycerol, 0.4% β-Mercaptoethanol and 1.2 10-4% Bromophenol blue). Then 
samples were electrophoretically resolved within reduced and denaturing polyacrylamide 
gels (8% or 10% polyacrylamide) and afterwards transferred to nitrocellulose membranes 
using Mini-Protean system (Bio-Rad) 380mA 1 hour and 45 min. Membranes were blocked 
for 1 hour in PBST (1X PBS – 0.1% Tween-20 (v/v)), containing 5% BSA (Sigma-Aldrich), 
and incubated overnight at 4°C with the antibodies (Table 1) diluted in PBST - 5% BSA. Per-
oxidase-conjugated polyclonal goat anti-rabbit (Dako ref.: P0448), peroxidase-conjugated 
polyclonal rabbit anti-mouse (Dako ref.: P0260), fluorophore-conjugated polyclonal donkey 
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anti-mouse (Li-Cor ref.: 926-68022) and fluorophore-conjugated polyclonal goat anti-rabbit 
(Li-Cor ref.: 926-32211) were used as secondary antibodies (at 1:5000 the peroxidase-con-
jugated and 1:2500 the fluorophore-conjugated) for 1 hour at room temperature in PBST - 
5% BSA. Bands were visualised with Super SignalTM chemiluminescent substrate (Thermo 
Fisher Scientific) in an ImageQuant LAS 4000 Mini (GE Healthcare Life Sciences), or with 
an Odyssey Infrared imaging system (B446-Li-Cor) in the case of the fluorophore-conjugated 
antibodies. Bands were quantified with ImageJ.
9.  Cholesterol quantification
Neuronal and hippocampi extracts were homogenised as previously described in MES 
buffer (see paragraph 7). Protein concentration was quantified using BCA assay kit. Then 
cholesterol quantification was determined per µg of protein using the Amplex® Red Choles-
terol Assay Kit (Invitrogen). Amplex Red kit allows cholesterol levels detection through trans-
formation of cholesterol molecules into 4-Cholesten-3-one plus H2O2 by means of Cholesterol 
oxidase activity. H2O2 generated is used by Horseradish peroxidase (HRP) enzyme for oxi-
dizing the Amplex Red compound, producing as a result Resorufin, a product that emits high 
fluorescence levels. After incubating samples with the Amplex Red solution (Amplex Red, 
HRP, Reaction buffer and Cholesterol oxidase), the fluorescence emitted was measured with 
a FluoStar OPTIMA (BMG labtech) fluorometer using 560 nm as excitation and 590 nm as 
emission wavelength.
10.  Immunoprecipitation
Protein concentration was quantified in hippocampal neuron extracts as previously 
described (see paragraph 7). Samples were pre-cleared using 25 µl protein A/G agarose 
beads (Santa Cruz ref.: SC-2003) and 10 µg of normal IgG (Santa Cruz ref.: SC-2025 for 
normal mouse IgG and SC-2027 for normal Rabbit IgG) for each 150 µg of protein. Samples 
were placed in a rotor for 1-3 hours at 4ºC. Then samples were centrifuged and the super-
natant collected. Afterwards the antibodies (Table 1) were added to the supernatant together 
with 25 µl protein A/G agarose beads and the mixture was incubated in a rotor overnight at 
4ºC. As a negative control non-immune normal IgGs were used in place of specific antibod-
ies. Immunoprecipitated complexes were washed four times with 1X PBS buffer plus 0.1% 
NP-40 (Sigma-Aldrich). Complexes were eluted with Laemmli Buffer for 5 min. at 99ºC and 
proteins were identified by Western Blot.
Materials & Methods
59
11.  Antibodies
Primary antibodies used for protein detection by Western Blot and Immunoprecipita-
tion. 
Table 1
  
 
 
  
Antibody Isotype Origin Reference Dilution WB 
Dilution 
IP 
-Tubulin Mo Abcam ab7291 1:10000   
-Actin Mo Sigma-Aldrich A5441 1:20000   
Gapdh Mo Abcam ab8245 1:20000   
Akt Rb Cell Signaling #9272 1:1000   
P-Akt (Ser473) Rb Cell Signaling #4060 1:1000   
Gsk3 /  Mo Invitrogen 44-610 1:1000   
P-Gsk3 /  (Ser9) Rb Cell Signaling #9331 1:1000   
IGF-1 Receptor  Rb Cell Signaling #9750 1:1000 1:100 
P-IGF-1 Receptor   
(Tyr1135/116) Rb Cell Signaling #3024 1:1000   
Insulin Receptor  Mo Santa Cruz SC-57342   1:100 
Insulin Receptor  Rb Santa Cruz SC-711 1:750   
P-Insulin Receptor  
 (Tyr1150/1151) Mo Millipore 04-299 1:750   
IRS-1 Rb Millipore 05-784 1:1000   
IRS-1 Mo 
BD 
Transduction 
Laboratories 
611394 1:1000   
P-IRS-1 (Ser312) Rb Abcam ab4865 1:750   
P-IRS-1 
(Ser636/639) Rb Cell Signaling #2388 
1:1000;  
1:200   
P-IRS-1 (Ser636) Rb Santa Cruz SC-101711 1:500   
SAPK/Jnk Rb Cell Signaling #9252 1:1000   
P-SAPK/Jnk 
(Thr183/Tyr185) Rb Cell Signaling #9251 1:1000   
p70S6 Kinase Mo 
BD 
Transduction 
Laboratories 
611260 1:1000   
P-p70S6 Kinase 
(Thr389) Mo Cell Signaling #9206 1:750  
Vinculin Rb Millipore AB6039 1:1000  
p38  Rb Cell Signaling #9218 1:750  
p38  Rb Abcam ab170099 1:1000  
P-p38 
(Thr180/Tyr182) Rb Cell Signaling #4511 1:750   
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12.  Insulin Receptor β sensitivity experiment
Insulin Receptor β sensitivity was determined in mouse hippocampus by measuring 
the capability of the receptor to become active upon ligand supply. For that purpose adult and 
old male mice were intraperitoneally injected with 27 IU/Kg body weight of human purified 
insulin (Actrapid®, Novo Nordisk) diluted in saline solution (0.9% NaCl). Injected mice were 
kept 1 hour at regular conditions (see paragraph 5) and then sacrificed. Hippocampi were 
extracted and processed as previously described. Samples were immunoprecipitated using 
an antibody against insulin receptor β and the level of receptor phosphorylation determined 
by Western Blot.
13.  Insulin Tolerance Test
Adult and old male mice were fasted for 4 hours in clean cages without any food. Glu-
cose concentration was determined in blood samples (from the tail vein) at the end of fasting 
(0 time-point) using an automatic analyser (Accu-Chek Aviva, Roche). Then fasted animals 
were intraperitoneally injected with 1IU/Kg body weight of human purified insulin (Actrap-
id®, Novo Nordisk) in saline solution (0.9% NaCl). Glucose concentration was determined at 
times 15, 30, 45 and 60 min. after insulin injection.
14.  Insulin-like growth factor-1 Receptor β activity 
Insulin-like growth factor-1 receptor β activity was measured by fluorescence reso-
nance energy transfer (FRET) in Hek 293T cells transfected with insulin-like growth factor-1 
receptor β extracellular and transmembrane regions fused to EYFP (FRET donor) or mCher-
ry (FRET acceptor), in the presence of IGF-1 or cholesterol oxidase (Choox). Plasmids were 
provided by Dr. Patrick. O. Byrne and Dr. Daniel J. Leahy from Johns Hopkins University 
School of Medicine, Baltimore, US (Kavran et al., 2014).
  
14.1  Plasmid expression:
Plasmids were expressed using 2 µl polyethylenimine (PEI) reagent (Polysciences 
ref.: #23966-2) for each 0.5 µg plasmid and 250 µl OPTIMEM (Gibco, Life Technologies Co.). 
Plasmid and PEI reagent were mixed in OPTI-MEM and incubated at room temperature for 
30 min. Then the mix was added to Hek 293T cells maintained in complete DMEM in a 1:5 
(v/v) proportion. Cells were incubated with transfection mix for 4 hours at 37ºC. Afterwards 
medium with 1:5 of transfection mix proportion was replaced by complete DMEM and cells 
were incubated at regular conditions. Expression of the transfected plasmid was detectable 
16 hours after transfection.
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14.2  Sample preparation: 
24 hours after transfection, cells were harvested and plated at 80% confluence into 
3.5 cm culture dish with 15 mm diameter coverslips previously coated with 1% poly D-Lysine. 
24 hours later cells were washed three times in 1X PBS to remove all traces of FBS and then 
serum starved in DMEM without FBS and Glutamine. After 5 hours of starvation 4µM IGF-
1 or 40 IU/ml Choox were added for 25 min. or 1 hour, respectively. Then the medium was 
removed and cells were washed once with 1X PBS, followed by 1% PFA fixation for 15 min. 
at room temperature. Finally PFA was removed and cells were washed four times in 1X PBS 
and mounted onto slides using Mowiol-Dabco (Mowiol, Chalbiochem) without antifading.
14.3  FRET (Fluorescence Resonance Energy Transfer): 
A confocal LSM710 microscope (Zeiss) coupled to an inverted AxioObserver Z1 mi-
croscope (Zeiss) was used for conducting acceptor photobleaching FRET experiments. Im-
ages were acquired using the following wavelengths: λexc=488nm, λem=503-532 for EYFP; 
λexc=561nm, λem=600nm-699nm for mCherry. Three pre-bleaching and four post-bleaching 
images were taken in both channels. Photobleaching was performed in delimited regions of 
interest (ROI) of the cells, in particular in the plasma membrane of the cells where the IGF-
1Rβ is mainly located under physiological conditions. Images were taking using a 63X oil 
objective and the ROIs used were squares of regular size. Acceptor signal was bleached up 
to a 5% of its initial magnitude applying the highest laser intensity during thirty iterations to 
the selected ROI. Zeiss imaging software was used to calculate FRET efficiency using the 
following equation:
FRET Efficiency (%)= [(Donorpost – Donorpre) / Donorpost] X 100
where Donorpre corresponds EYFP signal before bleaching and Donorpost corresponds 
to final EYFP signal after bleaching. All images were background-subtracted. Different con-
ditions were used in order to determine the presence of FRET upon cholesterol removal 
from the plasma membrane: Control situation, where cells were incubated only with starving 
medium; positive control situation where starving cells were incubated with IGF-1 peptide, 
the specific ligand for the protein that was being studied; study situation where starving cells 
were incubated with Choox in order to determine if this stimulus was able to induce FRET and 
subsequently approximation of the IGF-1Rβ homodimers. Three independent experiments 
for each of the three conditions were performed. Forty images in each condition and each 
experiment were subjected to acceptor-photobleaching technique and used to determine de 
FRET efficiency of IGF-1Rβ upon Choox treatment. 
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15.  Electrophysiology, Insulin-LTD
Adult and old mice (see paragraph 5) were tested for synaptic plasticity in the hip-
pocampal CA1-region in vitro. Animals were killed by cervical dislocation and the hippocam-
pus was rapidly dissected out into ice-cold (4ºC) ACSF saturated with carbogen. ACSF for 
electrophysiology experiments consisted of: 124 mM NaCl, 4.9 mM KCl, 24.6 mM NaHCO3, 
1.20 mM KH2PO4, 2 mM CaCl2, 2 mM MgCl2, 10 mM glucose, pH 7.4. Transverse slices (400 
µm thick) were prepared from the dorsal area of the right hippocampus with a tissue chopper 
and placed into a submerged-type chamber, where they were kept at 32ºC and continuously 
perfused with ACSF at a flow-rate of 2.2 ml/min. After 90 min. incubation, one slice was arbi-
trarily selected and a tungsten electrode was placed in CA1 stratum radiatum. Field excita-
tory postsynaptic potentials (fEPSPs) were recorded by placing a glass electrode (filled with 
ACSF, 3–7MΩ) in the stratum radiatum opposite the stimulating electrode. The time course 
of the field EPSP was measured as the descending slope function for all sets of experiments. 
After input/output curves had been established, the stimulation strength was adjusted to elicit 
a fEPSP-slope of 35% of the maximum and kept constant throughout the experiment. During 
baseline recording, 3 single stimuli (0.1 ms pulse width; 10 s interval) were measured every 5 
min. and averaged for the 60 min. fEPSP values. Unless otherwise stated, insulin-mediated 
LTD was achieved by application of 500 nM insulin dissolved in ACSF for 30 minutes (Van 
Der Heide et al., 2005, Huang et al., 2004). During peptidergic induction, evoked responses 
were monitored 1, 4, 7 and 10 min. and then continually every 5 min. as above. Insulin (500 
nm) was applied for 30 min., commencing at time zero; drug or test substances were applied 
30 min. prior to until 30 min. after the start of insulin application (zero point). 
Insulin was purchased as a desiccated powder and reconstituted according the manu-
facturers’ instructions  (Selleck Chemicals). The following compounds were used: Quercetin 
(Sigma-Aldrich ref.: Q4951) tested at 20 µM dissolved in ACSF; Wortmannin (Tocris ref.: 
1232) used at 0.5 µM; SB203580 (Axon Medchem ref.: 1363) dissolved in 50% ethanol and 
used at 0.5 µM; PH797804 (Selleck Chemicals ref.: S2726) dissolved in DMSO and used 
1µM; SP600125 (Tocris ref.: 1496) dissolved in DMSO and used at 1µM and Voriconazole 
(HangZhou Dayangchem Co.) tested at 10nM. The final concentration of the vehicle used 
either ethanol or DMSO was to 0.02% v/v in ACSF. In several studies, the vehicle alone was 
tested to establish that this did not affect Insulin-LTD.
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16.  Statistical analysis
Statistical analyses were performed with Graphpad Prism 5 (Graphpad Software Inc.). 
All values are presented as mean ± SEM (standard error of the mean). Data normality and 
variances were tested by Shapiro-Wilk test. Mann-Whitney U-test, Kruskal-Wallis or Fried-
man test, with Dunn’s adjustment for multiple comparisons, were used for nonparametric 
data. Student’s t-test or ANOVA with Bonferroni’s adjustment for multiple comparisons were 
used for parametric data. Asterisks in the figures indicate P values as follows: *<0.05; **<0.01; 
***<0.001.
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1.  Alterations in insulin signalling in old mice 
1.1  Insulin-LTD is impaired in old mice:
Previous findings have revealed that the application of insulin to the hippocampus of 
young mice and rats leads to a significant depression of excitatory activity. This process is 
called insulin-dependent long-term depression or Insulin-LTD (Beattie et al., 2000; Lin et al., 
2000; Man et al., 2000; Huang et al., 2003). 
To determine the effect of age on this synaptic plasticity event, hippocampal slices 
from adult (7-12 month-old) and old mice (20-24 month-old) were incubated in the presence 
of 0.5 µM insulin during 30 minutes. Analysis of the electrical response during the following 4 
hours revealed significant age differences:  insulin application caused a 20% depression of 
transmission at 3 hours after insulin addition, reaching a maximum of 30% reduction after 4 
hours, in slices from adult mice but not in slices from old mice, which did not show any de-
pression (Fig. R1). This result indicates that age impairs Insulin-LTD.
1.2  Insulin signalling upregulation leads to pathway desensitisation in old mice:
In order to determine the mechanism underlying reduced Insulin-LTD in the hippocam-
pus of old mice, we investigated the state of activity of insulin signalling (post-receptor) inter-
mediaries. It is well known that activation of the insulin receptor (IR) and insulin-like growth 
factor-1 receptor (IGF-1R) leads to the phosphorylation of PI3K (phosphatidylinositol 3-ki-
nase). PI3K then phosphorylates lipids on the plasma membrane, forming second messen-
* 
Adult mice 
Old mice 
Adult mice 
Old mice 
1 mV 
10ms 
240 min. 
60 min. 
Basal 
240 min. 
60 min. 
Basal 
Figure R1. Insulin-LTD is impaired in old mice hippocampus.
Graph showing Insulin-LTD induction in adult mice (7-12 month-old; ○ grey filled; n=10) and old mice slices 
(20-24 month-old; ♦; n=7). Insulin 0.5 µM was perfused in ACSF for 30 min. The grey box indicates the time 
of insulin perfusion. The kinetic curves represent the field excitatory postsynaptic potentials (fEPSPs) as % 
baseline. The sample traces on the right represent the electric signal at different time points: Basal, 60 min. 
and 240 min. Data are represented as mean ± SEM (One-way Anova; *p<0.05).
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ger phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Akt, a serine/threonine kinase, is re-
cruited to the membrane by interaction with these phosphoinositide docking sites, so that it 
can be fully activated. Once activated by insulin, Akt mediates a number of downstream re-
sponses, including protein-synthesis mediated internalisation of AMPA receptors and LTD 
(Huang et al., 2004). Thus, the absence of Insulin-LTD in old mice hippocampi made us envi-
sion that the PI3K/Akt pathway could be inhibited in the hippocampus of old mice. Quite the 
contrary, as we observed that Akt was strongly activated in old mice respect to adult mice 
(Fig. R2A). 
To confirm Akt activation in these samples, we checked the levels of a known down-
stream Akt target, the Serine 9 inhibiting mark in Gsk3β. In agreement with the strong Akt ac-
tivity, Gsk3β showed higher levels of its inhibitory mark in old mice (Fig. R2B). In order to test 
if the high PI3K/Akt pathway activity plays a role in the Insulin-LTD impairment observed in 
old mice, we inhibited PI3K/Akt signalling during stimulation of hippocampal slices with insu-
lin, following the same protocol as before (see Fig. R1). Both Wortmannin, a canonical PI3K 
inhibitor, and the naturally found flavonoid Quercetin, which efficiently inhibits Akt (Gulati et 
al. 2006), were capable of recovering the sensitivity to exogenous insulin in hippocampal 
slices from old mice (Fig. R3A-B). The lack of insulin function in the old hippocampus in spite 
of high downstream (PI3K/Akt) activity could be explained by the occurrence of insulin path-
way resistance due to pathway desensitisation, leading to the failure of hippocampal neurons 
to respond normally to this hormone.
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Figure R2. High levels of 
active Akt and inhibited 
Gsk3β in old mice hip-
pocampus. 
(A) Detection by Western 
Blot (WB) of active Akt levels 
using an antibody against the 
Akt activating mark Phospho-
Serine 473. The levels of ac-
tive Akt were measured in 
hippocampal extracts of adult 
(7-12 month-old) and old 
(20-24 month-old) mice. (B) 
Levels of the Gsk3β inhibit-
ing mark Phospho-Serine 9 
detected by WB in hippocam-
pal extracts of adult and old 
mice. Data are represented 
as mean ± SEM (t-test; 
*p<0.05).
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Both in intact animals and in cultured cells, different factors (i.e. chronic stimulation by 
insulin, free fatty acids) can lead to insulin resistance due to desensitisation and downregula-
tion of insulin signalling (Zick et al., 2001, Shah et al., 2004). One of the main effectors of this 
phenomenon is ribosomal protein S6 kinase beta-1 (S6K1), also known as p70S6 kinase 
(p70S6K, p70-S6K). In physiological conditions, its phosphorylation by the PI3K/Akt pathway 
induces the phosphorylation of the insulin receptor substrate 1 (IRS-1) at certain residues, 
mainly Serine 632 and Serine 307 leading to the termination of the insulin signalling (Um et 
al., 2004). Then, in the high PI3K/Akt background of the old hippocampus (see Fig. R2), we 
found reasonable to expect higher activity of p70S6K and negative phosphorylation of IRS-1. 
To investigate this possibility, we checked the levels of activation of p70S6K and of IRS-1 
negative phosphorylation in hippocampal fractions from adult and old mice. In accordance 
A 
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Old mice + Wortmannin 
Old mice 
Old mice + Quercetin 
0.5 mV 
10ms 
Old mice + Wortmannin 
Old mice + Quercetin 
0.5 mV 
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240 min. 
60 min. 
Basal 
240 min. 
60 min. 
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Figure R3. PI3K/Akt signalling inhibition restores Insulin-LTD in old mice hippocampus.
(A) Graph showing Insulin-LTD induction in hippocampal slices from old mice incubated with the PI3K inhibitor 
Wortmanin: untreated slices (●; n=7) and treated with Wortmannin (○ grey filled; n=7). (B) Graph represent-
ing Insulin-LTD induction in old mice hippocampal slices treated with the Akt inhibitor Quercetin: untreated (●; 
n=7) and treated (▲; n=8). In both cases insulin 0.5 µM was perfused in ACSF for 30 min. Wortmannin 0.5 µM 
or Quercetin 20 µM were perfused for 60 min. starting 30 min. before insulin stimulus. The black box indicates 
time of insulin perfusion. The grey box indicates the time of inhibitors perfusion. The kinetic curves represent 
the fEPSPs as % baseline. The sample traces on the right represent the electric signal at different time points: 
Basal, 60 min. and 240 min. Old mice traces remain the same as reflected in Fig. R1. Data are represented as 
mean ± SEM (One-way Anova; *p<0.05).
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with post-receptor pathway desensitisation, old mice presented higher p70S6K activity and 
IRS-1 negative marks (Serine 632 and Serine 307 phosphorylation) compared to adult mice 
(Fig. R4A-C). 
1.3  Insulin desensitisation in old mice hippocampus is consequence of a higher basal level 
of receptor activity:
In the insulin desensitisation state, the serine phosphorylated IRS-1 is refractory to 
stimuli (Zick et al., 2001). Moreover, in this state there is also a reduction in the competence 
of the insulin receptor to be activated by ligand (Um et al., 2004). To further prove that the 
ability of the hippocampus to sense the insulin signalling is compromised with age, we in-
jected adult and old mice intraperitoneally with 27 IU/Kg body weight of insulin. One hour 
after injection we extracted the hippocampus and we measured the level of receptor’s activity 
(reflected by receptor tyrosine phosphorylation). In agreement with insulin’s pathway desen-
sitisation in the old, only in injected adult mice the exogenous insulin led to strong receptor 
activation, while the response in old mice was minimal (Fig. R5). 
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Figure R4. Increment of insulin desensitising marks with ageing.
(A) WB showing increased activating mark Phospho-Threonine 389 on p70S6K in hippocampal extracts from 
old mice. (B) and (C) Detection by WB in adult and old mice hippocampal extracts of insulin desensitising marks 
on the  insulin receptor substrate 1 (IRS-1): Phospho-Serine 632 (centre) and Phospho-Serine 307 (right). Data 
are represented as mean± SEM (t-test for p70S6K and Ser307; Mann-Whitney U-Test for Serine 632; *p<0.05; 
**p<0.01).
Results
71
Previous publications from our group described that age increases the level of activ-
ity of the TrkB receptor, (Martin et al., 2008), a protein of the same receptor tyrosine kinase 
(RTK) family as IR and IGF-1R.  The lack of receptor response to insulin stimulus in the hip-
pocampus and the desensitisation observed in the pathway, together with these previous 
publications, prompted us to explore the possibility that IR basal activity would be increased 
in the old hippocampus. In order to make this study more comprehensive we also analysed 
the basal level of activity of the IGF-1 receptor, which shares downstream effectors with the 
IR and can also induce IRS-1 protein inhibition and therefore insulin desensitisation when 
persistently activated (reviewed in White, 2002; Dávila et al., 2008, Garwood et al., 2015). 
Consistent with the view that age affects both IR and IGF-1R-mediated signalling, we ob-
served higher levels of active IR and IGF-1R in hippocampal membranes from old mice com-
pared to adult mice (Fig. R6A-B), suggesting that desensitisation comes, to a certain extent, 
from the constitutive and high activity of the insulin and insulin-like growth factor-1 pathways. 
Insensitive insulin receptor and desensitised post-receptor activity are typical features 
of T2DM and are also observed in pre-diabetic conditions in old individuals, rising the possi-
bility that hippocampal insulin desensitisation in the hippocampus of old mice is the brain 
manifestation of systemic insulin resistance. To address this possibility, we assessed wheth-
er our old mice suffered from a pre-diabetic condition or not by performing the insulin toler-
ance test. In this test, insulin is injected intraperitoneally (1 IU/Kg body weight) after 4 hours 
of fasting and then blood glucose content is measured at different time points. The result of 
this experiment revealed that the old mice utilised in our studies had a slight but non-signifi-
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Figure R5. Reduced insulin sensitivity in the hippocampus of old mice. 
Adult and old mice were injected with saline solution (0.9% NaCl; Veh) or insulin 27IU/kg body weight (Ins) intra-
peritoneally and sacrificed after 1 hour. Hippocampal IRβ receptor was immunoprecipitated followed by detection 
of levels of activity by western blotting using the IRβ Phospho-Tyrosine 1150/1151 antibody. Data are represented 
as mean ± SEM (Two-way Anova with Bonferroni’s adjustment; *p<0.05; ns=not significant).
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cant reduced capacity to clear glucose from the blood (Fig. R7A-B), suggesting that hip-
pocampal insulin resistance is, to a significant extent, a brain autonomous process. 
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Figure R6. High basal levels of IRβ and IGF-1Rβ activity in the hippocampus of old mice.
(A) Detection of IRβ basal activity in adult and old mice hippocampus. The activity mark Phospho-Tyrosine 
1150/1151 was detected by western blotting after immunoprecipitation of total IRβ in hippocampal extracts 
of adult and old mice. (B) IGF-1Rβ basal activity detection in adult and old mice. The activity mark Phospho-
Tyrosine 1135/1136 was detected by western blotting after total receptor immunoprecipitation.  Data are rep-
resented as mean ± SEM (t-test; *p<0.05).
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Figure R7. Old mice hippocampal insulin desensitisation is independent of systemic insulin resist-
ance. 
Insulin Tolerance Test (ITT) performed in 4 hours fasted adult and old mice. After a time zero measure of blood 
glucose, mice were injected with Insulin 1IU/kg body weight intraperitoneally and blood glucose was measured 
every 15 min. during 1 hour. Measures are represented in percentage respect to the 0 point (A) or as area un-
der the curve (B). Data are represented as mean ± SEM (Two-way Anova with Bonferroni’s adjustment; t-test 
for area under the curve; ns=not significant).
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2.  Cholesterol addition rescues insulin pathway upregulation and desensitisa-
tion
2.1  Age-associated hippocampal cholesterol loss plays a role in hippocampal insulin resist-
ance:
The maintenance of the integrity and the optimal properties of the plasma membrane 
are an absolute prerequisite for the proper function of cells. In addition to their well known role 
in the maintenance of cell architecture and control of ion permeability, it is now well known 
their important role in the regulation of cell growth and adhesion, neurotransmission, biosyn-
thesis of biomolecules, regulation of enzyme activity and intracellular signalling (Ginsberg et 
al., 1982; Goldberg et al., 1986; Krischer et al., 1993; Glynn et al., 2013; MacDonald et al., 
2015). Numerous works have demonstrated that the lipid composition of neurons’ plasma 
membrane changes with age, both in animal experimental models and in humans (reviewed 
in Martin et al., 2014a; Colin et al., 2016) and also in the context of insulin resistance and 
T2DM (Bryszewska et al., 1986; Watala et al., 1990; Bakan et al., 2006). Most significant is 
the reduction in hippocampal (synaptic) plasma membrane cholesterol that occurs with age 
(Sodero et al., 2011; reviewed in Colin et al., 2016). Hippocampal cholesterol reduction with 
age impairs NMDA-mediated LTD and NMDA-mediated gene expression (Martin et al., 
2014b; Palomer et al., 2016a).  Hence, constitutive decrease of cholesterol in the hippocam-
pus of mice could play a role in hippocampal insulin function deficiency. In agreement with 
previous findings, the cholesterol levels were 20% reduced in hippocampal membrane ex-
tracts from old mice compared to adult mice (Fig. R8A). 
Figure R8. Hippocampal 
cholesterol levels decrease 
with age.
(A) Plot showing cholesterol 
quantification in adult and old 
mice hippocampal samples. 
(B) Quantification of cholester-
ol levels in old mice hippocam-
pal slices after replenishment 
with  a Methyl-β-cyclodextrin-
cholesterol (MβCD-Ch) mix 
(30 µM and 5 µM, respective-
ly). Data are represented as mean ± SEM (t-test; Mann-Whitney U-Test for (B); *p<0.05; **p<0.01).
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To investigate the implication of the age-associated cholesterol loss in insulin desen-
sitisation with age, we incubated hippocampal slices from old mice with exogenous choles-
terol, using Methyl-β-cyclodextrin-cholesterol (MβCD-Ch) at 30 µM cholesterol for one hour 
(see materials and methods). This treatment restored cholesterol content back to 95%, just 
slightly lower than the levels of adult mice (Fig. R8B). Having established the rescue value of 
exogenous cholesterol, we next investigated whether cholesterol addition was sufficient for 
attenuating the PI3K/Akt increased signalling observed in the non-treated old (see Fig. R2). 
Consistent with a true functional association, cholesterol addition reduced the levels of Akt 
phosphorylation at Serine 473, and also the activating mark on the downstream protein in the 
cascade p70S6K Threonine 389 (Fig. R9A-B). 
2.2  Cholesterol addition rescues IRS-1 desensitisation and Insulin-LTD:
To confirm that the cholesterol-based attenuation of PI3K/Akt phosphorylation was 
functionally relevant (i.e. permitted insulin action), we next performed two types of experi-
ments; biochemical and electrophysiological. Biochemically, the desensitisation marks ob-
served in old mice were reduced upon cholesterol increase. Fig. R10A-B shows that the 
addition of cholesterol to old mice hippocampal slices reduced the levels of Serine 632 and 
Serine 307 phosphorylation on IRS-1. 
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Figure R9. Cholesterol re-
plenishment reduces Akt 
signalling in old mice hip-
pocampal slices.
(A) Detection by WB of Akt 
Phospho-Serine 473 ac-
tivating mark in old mice 
hippocampal slices re-
plenished with cholesterol 
using the MβCD-Ch mix 
(see Fig. R8). (B) Levels of 
p70S6K activity determined 
by Phospho-Threonine 
389 activating mark in old 
mice hippocampal slices 
treated with the MβCD-Ch 
mix. Data are represented 
as mean ± SEM (t-test; 
*p<0.05).
Results
75
For the electrophysiology validation, we incubated hippocampal slices from old mice 
with the cholesterol-cyclodextrin mix (see above for the rescue value of this strategy) prior to 
the incubation with insulin and then recorded electrical activity for 4 hours as usual. Confirm-
ing that cholesterol loss plays a role in the poor insulin function in the old, the cholesterol 
addition allowed insulin to elicit LTD in old mice with an intensity similar to that of insulin in 
adult mice (Fig. R11A). Concomitantly with the rehabilitation of the synaptic plasticity signal-
ling, the levels of the inhibitory mark Serine 9 on Gsk3β, protein required for the crucial LTD 
step of GluR2 (AMPAR) internalisation, were reduced after cholesterol addition (Fig. R11B). 
Altogether, these last series of results indicate that one of the mechanisms by which age 
impairs the proper functioning of insulin in the hippocampus is through the loss of minimal but 
significant amounts of cholesterol. 
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Figure R10. Insulin desensitising 
marks are reduced upon choles-
terol addition.
(A) WB showing reduced levels 
of IRS-1 Phospho-Serine 632 in 
old mice hippocampal slices after 
MβCD-Ch treatment. (B) Levels of 
IRS-1 Phospho-Serine 307 desen-
sitising mark detected by WB in 
old mice hippocampal slices upon 
cholesterol replenishment. Data are 
represented as mean ± SEM (t-test; 
*p<0.05).
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Figure R11. Cholesterol addition 
rescues Insulin-LTD in old mice 
hippocampus.
(A) Graph showing Insulin-LTD induc-
tion in old mice slices (●; n=7) and 
old mice slices perfused with MβCD-
Ch (empty ♦; n=9). Insulin 0.5 µM 
was perfused in ACSF for 30 min. 
The MβCD-Ch mix was perfused for 
60 min. starting 30 min. before insu-
lin stimulus. The black box indicates 
time of insulin perfusion. The grey 
box indicates the time of MβCD-Ch 
perfusion. The kinetic curves repre-
sent the fEPSPs as % baseline.
Legend continues at the bottom of 
next page.
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3.  Cholesterol loss is sufficient to induce insulin pathway desensitisation
3.1  Cholesterol loss causes insulin pathway upregulation:
To further assess the role of age-associated cholesterol loss in brain insulin resistance 
with age we performed a series of sufficiency experiments: i.e. removed a small amount of 
cholesterol to young neurons followed by the analysis of insulin signalling. The prediction was 
that if the levels of this sterol were involved, a reduction in cholesterol content would lead to 
the over-stimulation of the insulin and IGF-1 pathways.  
We first analysed the levels of activity of the IR/IGF-1R under reduced cholesterol 
conditions in cultured hippocampal neurons. Endogenous cholesterol was reduced by the ad-
dition of 10 IU/ml Cholesterol oxidase (Choox) for 30 min. This protocol has been previously 
used allowing us to achieve a significant reduction of plasma membrane cholesterol without 
affecting cell viability (Brachet et al., 2015; Palomer et al., 2016b). Consistent with a role in 
insulin resistance, the reduction of cholesterol led to an increase in IR/IGF-1R activity (Fig. 
R12A-B). Next, we checked the effect of cholesterol removal on other members of the signal-
ling cascade. As shown in Fig. R13A-B, cholesterol removal effectively induced the activation 
of the downstream IR/IGF-1R effectors Akt and p70S6K. 
Figure R12. Cholesterol reduction increases IRβ and IGF-1Rβ basal activity in hippocampal neurons 
in culture.
(A) Detection of active IRβ in cultured neurons before and after cholesterol oxidase (Choox) treatment. WB 
of activity levels (determined by Phospho-Tyrosine 1150/1151 residues) in IRβ after immunoprecipitation with 
total IRβ antibody. (B) Levels of activity residues in IGF-1Rβ (Phospho-Tyrosine 1135/1136) after immuno-
precipitation with total IGF-1Rβ antibody. Choox treatment was 10 IU/ml for 30 min. Data are represented as 
mean ± SEM (t-test; *p<0.05).
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Figure R11. The sample traces on the right represent the electric signal at different time points: Basal, 60 min. 
and 240 min. Old mice traces remain the same as reflected in Fig. R1. (B) Detection by WB of Gsk3β Phospho-
Serine 9 inhibiting mark in old mice hippocampal slices replenished with cholesterol using MβCD-Ch. Data are 
represented as mean ± SEM (One-way Anova for (A); t-test for (B); *p<0.05; **p<0.01).
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3.2  Cholesterol loss induces insulin desensitising marks: 
Considering that both receptors, insulin and IGF-1, share post-receptor effectors, the 
increased activity of IR and IGF-1R in the low cholesterol/ageing condition suggests that this 
could be the mechanism underlying age-associated insulin desensitisation. In order to vali-
date this assumption, we checked the levels of insulin desensitising marks in neurons with 
reduced cholesterol. 
Figure R13. Cholesterol 
reduction increases Akt 
activity.
(A) WB reveals higher levels 
of Akt activity (Phospho-Ser-
ine 473), after cholesterol 
depletion using Choox. (B) 
WB reveals high levels of 
active p70S6K (Phospho-
Theronine 389) in cultured 
hippocampal neurons with 
reduced cholesterol (Choox-
treated) levels. Data are rep-
resented as mean ± SEM (t-
test; **p<0.01; ***p<0.001).
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Figure R14. Cholesterol 
reduction increases the 
levels of insulin desensi-
tising marks.
(A) WB of IRS-1 Phospho-
Serine 632 desensitising 
mark levels in cultured neu-
rons after Choox treatment. 
(B) WB of IRS-1 Phospho-
Serine 307 desensitising 
mark in hippocampal neu-
rons in culture after cho-
lesterol reduction. Data 
are represented as mean ± 
SEM (t-test; *p<0.05).
Results
78
Consistent with the prediction, cholesterol reduction led to higher levels of IRS-1 Ser-
ine 632 and Serine 307 phosphorylation (Fig. R14A-B). To determine if the cholesterol re-
moval affects the capability of young neurons to respond with LTD to insulin application, we 
analysed the activity of Gsk3β, a key determinant of the GluR2 internalisation needed for 
LTD. In agreement with this possibility, the reduction of cholesterol led to higher levels of in-
hibited Gsk3β (Fig. R15). 
3.3  Cholesterol loss allows spontaneous activation of insulin/IGF-1 receptors:
Next, we investigated the mechanism by which the loss of cholesterol leads to the ac-
tivation of the insulin and IGF-1 pathways. As mentioned in the Introduction both insulin and 
IGF-1 receptors are very similar in structure and activate the same downstream signalling 
pathway. Moreover, in order to become active both receptors require insulin or IGF-1 binding 
to their extracellular domain, inducing a conformational change in their transmembrane do-
main which leads to the physical approaching and autophosphorylation of their cytoplasmic 
tails (Hubbard et al., 1994 and 1997; Favelyukis et al., 2001; Lemmon et al., 2010; Kavran 
et al., 2014). Therefore, we speculated that the cholesterol loss observed in old mice could 
induce insulin/IGF-1 receptor subunits approximation and activation, in a manner similar to 
that induced by ligands. In order to test this possibility, we used full-length IGF-1R construc-
tions bearing fluorescent donor or acceptor tags in the intracellular domain (as in Kavran 
et al., 2014). We performed FRET efficiency analysis of these constructs co-transfected in 
Hek 293T cells, following a previously established protocol (see materials and methods and 
Kavran et al., 2014). The experimental design is shown in Fig. R16A-D. 
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Figure R15. Increased levels of Serine 9 Gsk3β inhibiting mark after cholesterol reduction.
WB of Gsk3β Phospho-Serine 9 levels in cultured hippocampal neurons after Choox treatment. Data are rep-
resented as mean ± SEM (t-test; ***p<0.001).
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We first determined the basal levels of FRET efficiency in transfected Hek 293T cells. 
We used the acceptor-photobleaching FRET where the approximation of the fluorescent mol-
ecules and transference of energy between them is measured by the increment of donor 
intensity upon acceptor photobleaching (see materials and methods). Fig. R17A shows the 
basal FRET efficiency (quantified in Fig. R18B). The addition of IGF-1 to transfected Hek 
293T cells caused an increase in the FRET efficiency, as reflected by the increment in the do-
nor signal after acceptor photobleaching (Fig. R17B). It is important to note that the increase 
in FRET indicates the receptor´s cytosolic domain approximation and that this is a sine qua 
non condition for autophosphorylation (Murakami et al., 1991; Hubbard et al., 1994). Hence, 
FRET increases indicate receptor activation. 
Figure R16. Simplified scheme of acceptor-photobleaching experiments.
FRET experiments are based on the capacity of one of the fluorophores of the pair to transfer energy to the 
other, also call FRET efficiency. In our experiments we transfected plasmids coding for IGF-1Rβ sequence 
modified through the addition at the cytosolic/kinase domains of a yellow (EYFP) or a red (mCherry) fluoro-
phore-coding sequence. (A) Conventional FRET response in the presence of ligand: induction of cytosolic 
domain approximation leading to increased FRET efficiency (transmembrane approximation leads to cyto-
plasmic approximation and autophosphorylation).  (B) Possible mechanism of cholesterol loss: cholesterol 
level reduction at the plasma membrane (right side of the dotted line) induces a conformational change in 
the IGF-1Rβ allowing the approximation of the kinase domains and thus increasing FRET efficiency. (C) The 
figure represents the FRET technique used: acceptor-photobleaching FRET. In this kind of FRET the intensity 
of donor fluorophore is measured after bleaching the acceptor. If there was FRET and energy was being trans-
ferred, the bleaching of the acceptor signal will increase the intensity of the donor signal and FRET efficiency 
will be higher. The diagrams are adapted from Kavran et al. 2014. (D) Lipids legend. 
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In this regard, removal of cholesterol in the absence of ligand led to an increase in 
FRET efficiency in the transfected Hek cells (Fig. R18A). The energy transfer obtained in the 
reduced cholesterol background was significant yet smaller than the increase achieved by 
the natural ligand (Fig. R18B). This is an expected outcome, consistent with insulin resist-
ance developing slowly, in parallel with the slow progression of brain cholesterol changes. 
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Figure R17. IGF-1 addition increases FRET efficiency of donor-acceptor fluorophore pair coupled to 
IGF-Rβ.
(A) and (B) Laser microscopy images of Hek 293T cells co-transfected with IGF-1Rβ-EYFP (donor fluoro-
phore) and IGF-1Rβ-mCherry (acceptor fluorophore), with the fluorophores replacing the cytosolic tails of the 
entire receptor sequence. Cells were starved for 5 hours and remained unstimulated (A) or were stimulated 
with 4 µM IGF-1 for 25 min. (B) before fixation. Acceptor signal was bleached, intensity of donor signal was 
measured and FRET efficiencies were calculated. Plots of FRET efficiencies are specified in Fig. R18. Scale 
bars represent 10 µm.
IGF-1R -EYFP IGF-1R -mCherry 
C
ho
ox
 P
re
-b
le
ac
hi
ng
 
C
ho
ox
 P
os
t-b
le
ac
hi
ng
 
A
0 
2 
4 
6 
8 
10 
Ctrl 
IGF-1 
Choox 
*** 
** 
Av
er
ag
e 
FR
ET
 E
ff.
 (%
) 
B
Figure R18. Cholesterol levels reduction increases FRET efficiency of donor-acceptor fluorophore pair 
coupled to IGF-1Rβ.
Legend continues at the bottom of next page.
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3.4  Cholesterol loss-mediated receptor activation determines pathway desen-
sitisation in hippocampal neurons:
In order to give neuronal “weight” to the Hek 293T cells’ results, we investigated the 
contribution of cholesterol-induced receptor activation in cultured hippocampal neurons. To 
address this possibility, low cholesterol-induced IR and IGF-1R activation (see Fig. R12) 
were incubated in the presence of the OSI-906 inhibitor, an ATP competitive inhibitor that 
avoids autophosphorylation of the IR and IGF-1R (Mulvihill et al., 2009). Inhibition of both 
receptors caused a significant, but not complete, reduction in the activation of Akt (Fig. R19A). 
Moreover, OSI-906 induced a significant reduction on Serine 632 phosphorylation of the IRS-
1 (Fig. R19B). Altogether these results reinforce the view that age-associated cholesterol loss 
participates in insulin desensitisation by, to a large extent, increased IR/IGF-1R activation. 
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Figure R19. IRβ and IGF-1Rβ activities are required for cholesterol removal-mediated high Akt activity and 
insulin desensitisation.  
(A) Cultured hippocampal neurons were pre-treated for one hour, previous to Choox treatment, with IRβ and 
IGF-1Rβ inhibitor OSI-906 (named Osi; 1 µM). Image shows detection by WB signal of Akt Phospho-Serine 473 
activating mark. (B) WB of IRS-1 Phospho-Serine 632 desensitising mark in cultured neurons, treated or not with 
OSI-906 previous to cholesterol removal with Choox. Data are represented as mean ± SEM (One-way Anova with 
Bonferroni’s adjustment; *p<0.05; **p<0.01; ***p<0.001; ns=not significant).
Figure R18. (A) Laser microscopy images of Hek 293T cells co-transfected with IGF-1Rβ-EYFP (donor fluoro-
phore) and IGF-1Rβ-mCherry (acceptor fluorophore), with the fluorophores replacing the cytosolic tails of the 
receptor. Cells were starved for 5 hours and then treated with 40 IU/ml Choox for one hour before fixation. 
Acceptor-photobleaching technique was performed, measuring the donor intensity increment that would reflect a 
higher FRET efficiency. Scale bar represents 10 µm. (B) Fig. R17 and Fig. R18 images’ quantification. Average 
FRET efficiency values for acceptor-photobleaching are plotted for each of the conditions: Control or unstimu-
lated, treated with IGF-1 ligand or with Choox. The graphic represents data obtained from 120 images quantified 
of three independent experiments for each condition. FRET efficiency was calculated as FRET Efficiency (%)= 
[(Donorpost – Donorpre) / Donorpost] X 100. Data are represented as mean ± SEM (Kruskall-Wallis test with Dunn’s 
adjusment; **p<0.01; ***p<0.001).
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4.  Additional mechanistic insights 
4.1  IGF-1R inhibition alone is not enough for reducing insulin desensitisation:
Regarding the demonstration that insulin desensitisation with age implies IR/IGF-1R 
activation by a cholesterol loss-mediated mechanism, we next checked the individual contri-
bution of IR and IGF-1R. First, we checked the effect of Picropodophyllin (PPP), the first 
specific IGF-1R inhibitor described not to interfere with IR (Girnita et al., 2004), in the Choox 
treated neurons. This inhibitor avoids substrate phosphorylation and autophosphorylation of 
the receptor. As shown in Fig. R20A exclusive inhibition of IGF-1R only moderately reduced 
the activation of Akt induced by cholesterol reduction. Consequently with the partial reduction 
of Akt signalling, the levels of the desensitising mark Serine 632 on IRS-1 were moderately 
reduced after cholesterol loss in the PPP treated cells (Fig. R20B). These results suggest the 
requirement of both receptors signalling, IR and IGF-1R, in the upregulation of the down-
stream pathway and posterior desensitisation through specific marks. 
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Figure R20. The inhibition of IGF-1Rβ alone is not sufficient to avoid cholesterol loss-mediated in-
crease in Akt activity and insulin desensitisation. 
(A) WB of Phospho-Serine 473 Akt activating mark after IGF-1Rβ inhibition with PPP (1 µM, 1 hour treatment) 
in reduced cholesterol neurons. (B) WB of PPP inhibitory effect on insulin desensitising mark IRS-1 Phospho-
Serine 632 after cholesterol removal with Choox. Data are represented as mean ± SEM (Friedman test with 
Dunn’s adjustment; *p<0.05; **p<0.01; ns=not significant). 
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4.2  Increased inflammation-associated signalling does not play a (major) role in reduced 
Insulin-LTD of the old:
Although we present a series of evidences consistent with the view that much of the 
insulin pathway desensitisation comes from receptor chronic activation of the PI3K/Akt path-
way, and by this mean the activation of the negative feedback loop leading to IRS-1 Serine 
307 and Serine 632 phosphorylation, insulin pathway desensitisation in the old hippocampus 
might have other origins.  In this sense, and most remarkable in the ageing context, are the 
several publications describing the occurrence of desensitising marks on the IRS-1 associ-
ated with inflammatory activity. A main target is however Serine 307 phosphorylation on IRS-
1, which is performed mainly by Jnk and also potentiated by others pro-inflammatory proteins 
like IKKβ (Aguirre et al., 2000; Yuan et al., 2001; Hirosumi et al., 2002; Tian et al., 2014). Also, 
inflammation-related increase in p38 activity has been related with insulin desensitisation 
(Jiang et al., 2004; Pereira et al., 2016; Nandipati et al., 2017). In view that both Jnk and p38 
activities increase in the brain with age (Hu et al., 2006; Zhou et al., 2009; Li et al., 2011; 
Orejana et al., 2013), we explored the possibility that the activation in aged mice of these 
pathways could have also contributed to the insulin desensitising signals observed in old 
mice. In support of this possibility the activity of Jnk and p38 were significantly increased in 
old mice hippocampus in vivo (Fig. R21A-B). 
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Figure R21. High activity of the MAPKinases Jnk and p38 in ageing mice hippocampus.
(A) WB of Jnk activity levels (Phospho-Threonine 183 and Tyrosine 185) in hippocampal extracts from adult 
and old mice. (B) WB of p38 activating marks Phospho-Threonine 180 and Tyrosine 182 detected in hip-
pocampal extracts from adult and old mice. Data are represented as mean ± SEM (t-test for 54kDa Jnk and 
p38; Mann-Whitney U-Test for 46kDa; *p<0.05).
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To test if these enzymes´ increased activity with age was related to the cholesterol 
loss that occurs during ageing, cultured hippocampal neurons were subjected to Choox treat-
ment followed by SDS PAGE and western blotting. Consistent with a cause-effect relation-
ship, the cholesterol reduction treatment revealed a significant increase in Jnk and p38 ac-
tivities in vitro (Fig. R22A-B). Therefore, we next checked if the inhibition of p38 and Jnk 
activity played a role in the increase in Serine 307 phosphorylation that occurs in response to 
the cholesterol reduction treatment. 
Figure R23. Inhibition 
of Jnk and p38 pre-
vents the insulin de-
sensitising mark on 
IRS-1.
(A) WB of insulin de-
sensitising mark IRS-1 
Phospho-Serine 307 
in cultured hippocam-
pal neurons. Neurons 
were treated with the 
Jnk inhibitor SP600125 
(named SP; 10 µM, 
1-hour treatment) be-
fore cholesterol reduc-
tion through Choox. 
(B) Levels of IRS-1 
Phospho-Serine 307 in 
neurons treated with the 
p38 inhibitor PH797804 
(named PH; 2 µM, 1 
hour treatment) before cholesterol levels reduction through Choox. Data are represented as mean ± SEM (One-
way Anova with Bonferroni’s adjusment; *p<0.05; **p<0.01; ns=not significant).
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Figure R22. Jnk and p38 ac-
tivation is increased in cul-
tured hippo-campal neurons 
after cholesterol removal with 
Choox. 
(A) WB of Jnk activating marks 
Phospho-Threonine 183 and Ty-
rosine 185 in cultured hippocam-
pal neurons after cholesterol 
removal with Choox. (B) WB of 
p38 activating marks Phospho-
Threonine 180 and Tyrosine 182 
detected in cultured hippocampal 
neurons after Choox treatment. 
Data are represented as mean ± 
SEM (t-test; *p<0.05; **p<0.01; 
***p<0.001).
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Consistent with this possibility, the inhibition of Jnk and p38 caused a reduction in 
Serine 307 phosphorylation levels in cultured hippocampal neurons (Fig. R23A-B). In order 
to determine the contribution of high Jnk and p38 activities in the poor insulin signalling of the 
old, we tested by electrophysiological means the effect of inhibiting these kinases´ activities. 
As shown in Fig. R24A-B, the inhibition of either Jnk or p38 did not result in the restoration of 
Insulin-LTD in hippocampal slices from old mice. These results suggest that the activation of 
inflammatory signalling, despite is contributing to insulin desensitisation, is not critically in-
volved in the poor electrophysiological response to insulin in the old hippocampus. Consider-
ing the Insulin-LTD recovery using Wortmannin and Quercetin (Fig. R3A-B) these data rein-
force the PI3K/Akt hyper-activation as the main event underlying poor Insulin-LTD in old 
mice. 
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Figure R24. Inhibition of MAPKs Jnk or p38 is not sufficient to rescue Insulin-LTD in old mice hip-
pocampus.
(A) Graph showing Insulin-LTD induction in old mice slices (♦; n=7) and old mice slices perfused with Jnk 
inhibitor SP600125 (○ grey filled; n=6). (B) Graph representing Insulin-LTD induction in old mice (♦; n=7), 
old mice + p38 inhibitor PH797804 (♦ grey filled; n=4) and old mice + p38 inhibitor SB203580 (□ grey filled; 
n=6). In both figures insulin 0.5 µM was perfused in ACSF for 30 min. SP600125 1 µM, PH797804 1 µM or 
SB203580 0.5 µM were perfused for 60 min. starting 30 min. before insulin stimulus. The black box indicates 
time of insulin perfusion. The grey box indicates the time of inhibitors’ perfusion. The kinetic curves represent 
the fEPSPs as % baseline. The sample traces on the right represent the electric signal at different time points: 
Basal, 60 min. and 240 min. Old mice traces remain the same as reflected in Fig. R1. Data are represented as 
mean ± SEM (One-way Anova; ns=not significant).
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5.  The CYP46A1 inhibitor Voriconazole rescues insulin desensitisation in old 
mice 
Although not investigated in depth, age-associated cholesterol loss in the hippocam-
pus is thought to be the consequence of a number of events, namely, i) reduced synthesis by 
neurons (Fünfschilling et al., 2007; Saito et al., 2009), ii) reduced synthesis in astrocytes, the 
main neuron-cholesterol delivering cells in the adult brain (Quan et al., 2003; Thelen et al., 
2006; Nieweg et al., 2009) and, perhaps the most relevant iii) increased expression levels 
and activity of the cholesterol catabolic enzyme cholesterol 24-hydroxylase, or CYP46A1 
(Lütjohann et al., 2000; Sodero et al., 2011). Consistent with this last possibility, the expres-
sion in the brain of this enzyme increases with age, both in rodents and in humans (reviewed 
in Martin et al., 2014a). The cause of the age-associated increase is not known, though the 
early demonstration that this enzyme is regulated at the transcriptional level by oxidative 
stress metabolites (Ohyama et al., 2006) would suggest that its activation in the old might 
obey to the same factors, which abundantly accumulate in ageing tissues.  Irrespective of the 
underlying mechanism of this enzyme´s activation, we tested its involvement in the age-as-
sociated insulin insensitivity. For this purpose, we inhibited the activity of this enzyme through 
the oral administration to old mice of the compound Voriconazole. 
Voriconazole is a triazole antifungal drug that presents high specificity for CYP46A1, 
both in vitro and in vivo (Shafaati et al., 2010). Importantly, the in vivo effects in the brain 
where observed after systemic administration, implying that this compound efficiently cross-
es the blood-brain barrier (Shafaati et al., 2010). Moreover, and consistent with this enzyme´s 
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Figure R25. Voriconazole 
treatment decreases Akt 
downstream signalling up-
regulation in ageing mice 
hippocampus.
(A) WB of Akt Phospho-Serine 
473 activating mark in hip-
pocampal extracts from old 
mice treated during 45 days 
with vehicle (Veh.) or the CY-
P46A1 inhibitor Voriconazole 
(Voric.). (B) Levels of p70S6K 
Phospho-Threonine 389 acti-
vating mark in the same hip-
pocampal extracts. Data are 
represented as mean ± SEM 
(t-test; *p<0.05).
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activity playing a role in the cognitive deficits of the old, a recent publication from our group 
revealed that the oral administration of Voriconazole to old mice prevents both, the loss of 
cholesterol that normally accompanies ageing and (some of) the cognitive deficits typical of 
this stage of life (Palomer et al., 2016b). Hence, we treated 20 month-old mice orally with a 
Voriconazole solution (60 mg/kg body weight/day) during 45 days and at the end of the treat-
ment studied the effect on insulin signalling. 
This experimental approach results in the significant reduction of the cholesterol loss 
accompanying ageing (Palomer et al., 2016b). In agreement with this result and with the pre-
vious rescue effects of exogenous cholesterol, (see Figs. R9-R11) this treatment efficiently 
reduced Akt and p70S6K activity in the hippocampus of old mice (Fig. R25A-B) and also the 
Serine 632 inhibitory mark on IRS-1 (Fig. R26). In addition, we observed that Voriconazole 
treatment also rescued the increment in old mice of some of the inflammatory proteins´ activ-
ity described to be upregulated upon cholesterol loss, like Jnk (fig. R27A). 
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Figure R26. Voriconazole treat-
ment reduces IRS-1 Phospho-
Ser632 in the hippocampus of 
old mice.
WB of IRS-1 Phospho-Serine 
632 desensitising mark in hip-
pocampal extracts of vehicle 
(Veh.) or Voriconazole (Voric.) 
treated old mice. Data are rep-
resented as mean ± SEM (t-test; 
*p<0.05).
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Figure R27. Voriconazole 
partially attenuates Jnk and 
p38 MAPKs’ activation in 
hippocampal extracts from 
old mice.
(A) WB of Jnk activating marks, 
Phospho-Threonine 183 and 
Tyrosine 185, in hippocampal 
extracts of old mice treated with 
Vehicle (Veh.) or Voriconazole 
(Voric.) for 45 days. (B) Levels 
of p38 Phospho-Threonine 180 
and Tyrosine 182 activating 
marks, detected by WB, in the 
same hippocampal extracts. 
Data are represented as mean 
± SEM (t-test; *p<0.05; ns=not 
significant).
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However, the treatment was not able to completely revert the inflammatory effect as-
sociated to old state, as p38 activity was not significantly reduced (fig. 27B). Nevertheless, 
and consistent to the higher influence described of Jnk over Serine 307 resistance mark 
performance (Aguirre et al., 2000; Shoelson et al., 2006), the treatment with Voriconazole 
reduced Serine 307 desensitising mark on IRS-1 protein (Fig. R28). 
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Figure R28. Voriconazole 
treatment reduces IRS-1 
Phospho-Ser307 in the hip-
pocampus of old mice.
Detection by WB of levels of 
insulin desensitising mark IRS-
1 Phospho-Serine 307 in hip-
pocampal extracts of vehicle 
(Veh.) or Voriconazole (Voric.) 
treated old mice. Data are rep-
resented as mean ± SEM (t-
test; *p<0.05).
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Figure R29. Voriconazole treatment rescues Insulin-LTD in hippocampal slices from old mice. 
(A) WB of Gsk3β Phospho-Serine 9 inhibiting mark in hippocampal extracts of old mice. Old mice were treated 
with Vehicle (Veh.) or Voriconazole (Voric.) (B) Graph showing Insulin-LTD induction in old mice slices (●; 
n=7) and old mice slices perfused with Voriconazole (▼; n=8). Insulin 0.5 µM was perfused in ACSF for 30 
min. Voriconazole 10 nM was perfused for 60 min. starting 30 min. before insulin stimulus. The black box indi-
cates time of insulin perfusion. The grey box indicates the time of Voriconazole perfusion. The kinetic curves 
represent the fEPSPs as % baseline. The sample traces on the right represent the electric signal at different 
time points: Basal, 60 min. and 240 min. Old mice traces remain the same as reflected in Fig. R1. Data are 
represented as mean ± SEM (t-test for for (A); One-way Anova for (B); *p<0.05). 
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To determine to which extent the rescue effects of the Voriconazole treatment on 
the insulin desensitisation marks were paralleled by a reduction in the marks that could be 
involved in the reduced Insulin-LTD of the old, we measured the levels of phosphorylation 
of Serine 9 at Gsk3β. As mentioned, Gsk3β is one of the proteins implicated in the GluR2 
internalisation required for the establishment of Insulin-LTD. In accordance with a close link 
between the reduction in the desensitisation marks and desensitisation mediators, Voricon-
azole treatment resulted in lower inhibitory phosphorylation of Gsk3β at Serine 9 (Fig. R29A). 
Finally, we tested if Voriconazole treatment was able to rescue the poor hippocampal Insulin-
LTD of old mice. Pre-incubation of old hippocampal slices with Voriconazole was sufficient to 
restore the ability of insulin to elicit LTD (Fig. R29B), all in all confirming the relevance of the 
CYP46A1 mediated pathway in the age-associated and cholesterol loss-dependent impair-
ment in brain insulin signalling. 
DISCUSSION
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1.  Reduced insulin signalling in the old brain: weaker plasticity in order to im-
prove survival?  
The results in this thesis provide insights into the phenomenon of insulin and insulin-
like growth factor-1 (IGF-1) signalling in the ageing brain. Due to the different and important 
processes these factors regulate, they have become especially relevant in ageing progres-
sion. The loss of insulin signalling, and to a great extend also IGF-1, is a known and well-
described event in old organisms. In fact, reduced insulin signalling is considered a hallmark 
of ageing with a most important physiological role: to improve survival (Fontana et al., 2010; 
Laplante et al., 2012). Works in different species suggest that this ligand-dependent activity 
reduction allows cells to minimise the anabolic processes triggered by these pathways and 
thus minimise the associated detrimental effects (mainly oxidative stress). In addition, insulin 
and IGF-1 signalling reduction favours the activation of several supports in the survival strug-
gle, e.g. different transcription factors expression associated to stress response like FOXO1 
(Van der Horst et al., 2007; Cohen et al., 2009). Besides, it leads to autophagy activation, 
a process implicated in the degradation of old and damaged organelles thus improving cell 
performance (Bjedov et al., 2010; López-Otín et al., 2013; Li et al., 2016). 
In the brain, insulin signalling presents a number of peculiarities compared with pe-
ripheral organ insulin function. In the brain, in addition to metabolic and cell growth signalling, 
insulin and IGF-1 pathways play an important role in synaptic activity (Huang et al., 2003 and 
2004; Wang et al., 2000). In particular, this function is supported by an activity-dependent 
tuning following release from presynaptic terminals upon depolarisation and the ulterior in-
fluence on electric transmission at the post-synapse (Wei et al., 1990; Van Der Heide et al., 
2005; Cao et al., 2011). This effect has been more widely studied in relation to long-term 
depression (Insulin-LTD) in the hippocampus, one of the brain regions underlying memory 
and learning (reviewed in Huang et al., 2009). Thus, the alteration in insulin/IGF-1 signalling 
with age will have an impact not only on metabolic processes but also on high order brain 
function. In accordance with this, defects in brain insulin signalling have been associated 
with the cognitive alterations that accompany brain pathologies of the elderly like Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) (Hu et al., 2007; Moloney et al., 2010; Perruolo 
et al., 2016). However, the precise molecular mechanisms of reduced brain insulin and IGF-1 
signalling in the ageing brain are not well known.  
Consistent with previous works, we also observed reduced insulin response in the 
old hippocampus. However, we found an increase in the basal activity of the whole pathway, 
beginning at the receptor level, affecting both IR and IGF-1R, which is transmitted to these 
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receptors´ downstream effectors PI3K/Akt and p70S6K. How a hyperactive pathway results 
in reduced signalling can be only explained through pathway desensitisation mechanisms, 
whereby constant activity leads to inhibition. In the case of the insulin and IGF-1 pathway the 
negative feedback that impedes continuous signalling (in turn avoiding deleterious effects of 
constitutive activity) is mediated by the induction of phosphorylation at serine residues (Ser-
ine 632 and Serine 307) in the IRS-1 scaffolding protein. While other groups have previously 
described similar events in the context of pathology, in particular in AD (An et al., 2003; Griffin 
et al., 2005; Talbot et al., 2012), and considered this a negative event, the fact that we ob-
serve the same in the normal ageing context, where there is no cell death, suggest that it may 
serve a beneficial role: to improve survival. In fact, the PI3K/Akt is one of the most conspicu-
ous survival pathways in the brain (Hetman et al., 2000; Chen et al., 2001; Kim et al., 2002; 
Tschopp et al., 2005; Miyawaki et al., 2009). On the other hand, it is clear that the activation 
of the PI3K/Akt pathway has negative consequences for synaptic plasticity. Thus, Akt inhibits 
Gsk3β by phosphorylating this enzyme at the Serine 9 residue, and this inhibition results in 
reduced AMPARs lateral diffusion and endocytosis and, consequently, impaired LTD (Du et 
al., 2010; Yagishita et al., 2015). Our results in old hippocampus confirm this negative out-
come: together with a higher Akt activity we report inhibited Gsk3β and, more importantly, 
absence of Insulin-LTD. All these results, added to our demonstration that Insulin-LTD can be 
rescued when the PI3K/Akt pathway is inhibited, are compatible with the view that an hyper-
active insulin/IGF-1 pathway contributes to the mild deficits in memory and cognition that 
characterise the late stage of life. A “master” determinant of this deficit seems to be the hy-
peractive PI3K/Akt: it induces the negative feedback on the IRS-1, blocking incoming insulin 
function  (Zick et al., 2001) and inhibits Gsk3β activity and by this means LTD (Peineau et al., 
2007). But, as said, the “bad” outcome of PI3K/Akt comes with a “good” counteraction, due to 
the role of the PI3K/Akt in cell survival.  We propose that these “good and bad” actions from 
the same pathway may reflect a “perform or survive” dilemma of old neurons. Old neurons 
are characterised by the presence of toxic material accumulated over years that interfere 
with function and, at the same time, with old and dysfunctional organelles (i.e. mitochondria 
and the proteasome). Because of these negative conditions function is impaired. Then, a 
big dilemma of an old neuron arises: reinforce performance or survival? From the data here 
presented it seems that the answer is an obvious one: survival. This cannot come as a sur-
prise as adaptation for survival is the most conserved mechanism of evolution. The price for 
survival is, apparently, the reduction in performance. 
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2.  On the association between brain insulin defects and peripheral insulin re-
sistance   
Numerous clinical retrospective studies and direct laboratory experimentation support 
the notion that insulin resistance favours the development of AD signs, by the direct effect of 
insulin resistance on brain cells  (Matsuzaki et al., 2010; Tolppanen et al., 2013). Therefore, 
a reasonable possibility to explain the reduced insulin signalling in the old brain is that our 
observations are a simple extension within the brain of whole body insulin resistance. This 
however does not seem to be the case.  The insulin tolerance test performed, that measures 
insulin sensitivity in peripheral tissues, failed to show significant differences between adult 
and old mice, of the same age that show the brain insulin signalling defects. Thus the results 
we obtained using hippocampal fractions seem to reflect a reduction in insulin sensitivity re-
strained to this brain structure, independently of the peripheral context. This however does 
not rule out that when peripheral insulin resistance develops it will further impact insulin 
sensing at the brain level. In any event, our results strongly suggest that hippocampal insulin 
resistance in the old develops independently from body insulin dyshomeostasis. 
3.  On the mechanism behind brain insulin resistance with age: age-associated 
cholesterol loss is implicated 
Activation of insulin/IGF-1 signalling pathways in the old brain could be due to differ-
ent events. One possibility is an increment in peptide/ligand availability to receptors, either 
because of larger passage from the circulation or because of increased synthesis.  In fact, 
brain cells are able to synthesise both peptides (Bach et al., 1991; Mehran et al., 2012) 
and both ligands have the capacity to cross the blood-brain barrier. It has been suggested 
that this double source of inputs allows a signalling compartmentalisation for both peptides, 
with the brain-external source mainly used in metabolic homeostasis and developmental 
processes, and the local synthesis responsible for synaptic plasticity modulations (Wei et 
al., 1990; Fernandez et al., 2012). In support that increased own synthesis might be one of 
the mechanisms contributing to insulin resistance in the old, we observed higher levels of 
IGF-1 mRNA in the hippocampus of old mice (Figure D1). Furthermore, we also observed 
enhanced expression of the insulin signalling facilitator GIP receptor, (Faivre et al., 2011; 
Paratore et al., 2011). On the contrary, a series of studies have shown that insulin and IGF-1 
production becomes reduced with ageing (D’Costa et al., 1995; Frölich et al., 1998; Lee et al., 
2014), leaving open the discussion about the role of ligand excess as one of the mechanisms 
for hippocampal insulin desensitisation with age. 
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Another mechanism that could lead to receptor activation and desensitisation is by 
age-associated changes in membrane lipid composition, which due to changes in the liquid 
order balance (rigidity/fluidity) would affect receptors´ lateral mobility, clustering and thus au-
tophosphorylation. In this sense, previous works in different laboratories, including ours, have 
demonstrated the existence of changes in different lipids in the ageing brain (see Colin et al., 
2016). Among the lipids that change in the ageing brain, and with a great potential to underlie 
signalling defects like the ones observed here, cholesterol loss acquires fundamental rel-
evance (reviewed in Martin et al., 2014a and Colin et al., 2016). In support that this may be a 
cause for the insulin signalling defects, the replenishment of cholesterol to the hippocampus 
of old mice reduced PI3K/Akt activity, prevented the occurrence of the negative phosphoryla-
tion on the IRS-1 protein and restored the functional sensitivity of old hippocampal neurons 
to exogenous insulin  (Insulin-LTD). In further support of a role as “maker” and not simply 
“marker” of insulin insensitivity, removing cholesterol from the plasma membrane of mature 
(not old) hippocampal neurons was sufficient to elicit biochemical desensitisation. It is impor-
tant to notice at this point that the cholesterol loss is likely to affect the level of activity of both 
insulin and IGF-1 receptors. Both receptors are structurally similar and their activation leads 
to the downstream activation of similar targets, being the PI3K/Akt node one of the important 
connections between both signalling factors (Taniguchi et al., 2006). The interrelation of both 
pathways is an important aspect in insulin-mediated synaptic plasticity, guaranteeing that 
this type of synaptic plasticity can occur in any place brain region, irrespective of which one, 
insulin or IGF-1, is made (Wang et al., 2000). 
Despite the clear effect that cholesterol loss exerts on insulin signalling in the old brain, 
one must not forget that:  i) cholesterol loss will have a panoply of consequences in addition 
to the one described here (this laboratory has demonstrated the effect of age-associated 
cholesterol loss in relation to other survival and plasticity events), including, possibly, glucose 
uptake and ii) the biological consequences of cholesterol loss with age cannot be dissociated 
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Figure D1. Insulin/IGF-1 related 
mRNAs are upregulated in old 
mice.
RT-qPCR analysis of IGF-1 pep-
tide (A) and Gip receptor (B) 
mRNA trans-cribed in adult and 
old mice hippocampus. Data are 
represented as mean ± SEM 
(Mann-Whitney U-Test for (A) and 
t-test for (B); *p<0.05).
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from the changes in other lipids of the neuronal plasma membrane with age, especially of 
those that constitute the core of the raft domains: i.e. sphingomyelin and gangliosides. These 
two important matters should be the subjects of future investigations.  
4.  Both insulin and IGF-1 receptors are activated by cholesterol loss, being 
responsible for (part of) PI3K/Akt high activity in the old hippocampus 
The results described point to cholesterol loss-mediated activation of the PI3K/Akt 
pathway as the master switch responsible for the insulin desensitisation observed in old 
mice. However, direct proof that the PI3K/Akt desensitisation came from a cholesterol loss-
mediated activation of the insulin or IGF-1 receptor was missing. We confirmed this to be the 
case by inhibiting the activity of both receptors in neurons with reduced cholesterol with the 
specific inhibitor Osi-906. This significantly reduced Akt activity and IRS-1 Serine 632 insulin 
desensitisation mark. It is worth clarifying that IGF-1R signalling inhibition alone did not show 
a significant reduction effect on any of the two parameters (PI3K/Akt and Serine 632 on IRS-
1), suggesting that desensitisation of the pathway is either the consequence of the IR alone 
or that joint signalling from both receptors is required. The use of IR specific inhibitor will help 
to clarify this issue. It is also worth pointing out that not all Akt activity was blocked with the 
IR and IGF-1R inhibitor. We attribute this partial effect to the contribution of other pathways 
activated by cholesterol loss, like that mediated by the TrkB receptor (Martin et al., 2008).  
In addition to cholesterol loss-PI3K/Akt-mediated insulin desensitisation coming from 
membrane receptors, pathway desensitisation may also be the consequence of the inflam-
mation that occurs in the brain of old subjects (Salminen et al., 2012). Two of the proteins 
tightly linked with inflammation, Jnk and IKKβ, have been described to trigger or promote 
respectively the inhibitory phosphorylations on the IRS-1 protein associated to insulin desen-
sitisation. In addition to the negative phosphorylation on this scaffold protein by the PI3K/Akt/
p70S6K cascade (Um et al., 2004), the IRS-1 residue Serine 307 can be negatively regulated 
by Jnk phosphorylation or by IKKβ (Aguirre et al., 2000; Yuan et al., 2001). Besides, different 
inflammatory effectors have been also linked with Serine 307 phosphorylation and insulin 
desensitisation, as it is the case of p38 (Al-Lahham et al., 2016; Pereira et al., 2016). From 
these series of observations, the arising conclusion is that hippocampal insulin desensitisa-
tion with age is not only the consequence of cholesterol loss on membrane receptors of the 
tyrosine kinase family (like IR, IGF-1R and TrkB) but also of age associated inflammatory 
conditions. When we tested this possibility we obtained mixed results: inhibition of Jnk and 
p38 reduced the negative phosphorylation on Serine 307 but it did not rescue Insulin-LTD. 
The simplest conclusion would be that despite increase inflammatory inputs leading to higher 
Discussion
98
negative phosphorylation on IRS-1, the abrogation of this effect is not enough to restore Insu-
lin-LTD. This is however an expected outcome, as lack of Insulin-LTD is the consequence of 
high PI3K/Akt (via inhibition of Gsk3β) and reduction of the negative phosphorylation on IRS-
1, despite ameliorating insulin’s sensitivity, does not reduce PI3K activity. Altogether these 
data point to the cholesterol loss as the main cause for IR/IGF-1R activation and posterior 
desensitisation in old mice. 
5.  Cholesterol loss induces insulin desensitisation through an enhancement 
of receptors´ autophosphorylation 
After we became convinced that plasma membrane cholesterol loss is a key event 
in the high PI3K/Akt activity in the hippocampus of old mice and that this is in turn a major 
determinant of insulin desensitisation, we then asked the simple question of how cholesterol 
loss induces high PI3K/Akt activity. Previous works have demonstrated that the mild mem-
brane cholesterol loss that occurs in the old is not severely deleterious to neurons, probably 
because the occurrence of major permeability and structural losses might be compensated 
by, among other mechanisms, changes in the levels of other lipid moieties, including sphin-
gomyelin (Trovò et al., 2011; Colin et al., 2016). This type of lipid re-arrangement of the 
plasma membrane is also evident in type 2 diabetes mellitus (T2DM) cells (Bryszewska et 
al. 1986; Watala et al., 1990; Bakan et al., 2006), being especially remarkable the tendency 
of membranes in diabetics to become more rigid, property that could affect receptors’ mem-
brane dynamics and activity (Pilon et al., 2016). In agreement with the possibility that the lipid 
changes could alter IR/IGF-1R activity directly, works from other laboratories have shown that 
a reduction in cholesterol levels in adipocytes affects IR signalling (Parpal et al., 2001). Like-
wise, chronic stimulation of adipocytes with TNFα alters cholesterol/gangliosides proportion 
leading to a shift in IR location to regions enriched in GM3 gangliosides and affecting post-
receptor signalling (Kabayama et al., 2005 and 2007). All these data reflect the importance of 
membrane composition in IR/IGF-1R signalling. In this sense, our FRET experiments directly 
prove that cholesterol loss induces a conformational change in the IR/IGF-1R similar to that 
triggered by ligand (Murakami et al., 1991; Hubbard et al., 1994; Kavran et al., 2014): i.e. 
approximation of the transmembrane and intracellular domains of the dimer subunits (from 
there the energy transfer), thus leading to receptor autophosphorylation and consequent 
activation. Although our experiments were conducted, for practical reasons, in IGF-1R do-
nor and acceptor transfected Hek 293T cells, we consider the increase FRET in these cells 
as the “proof-of-concept” that a chronic and steady cholesterol loss can directly determine 
pathway desensitisation by enhancing receptors´ activity. Nevertheless, further experiments 
are required in order to determine if changes in membrane fluidity in neurons from old mice 
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are behind these receptors high basal activity. In any event, the results here presented pave 
the way to determine if the mechanism here described for the insulin and IGF-1 receptors 
is translatable to other types of receptors that also require clustering in cholesterol-rich do-
mains. In relation to this possibility, preliminary results based on the use of a kinase-based 
screen for 36 receptor tyrosine kinases (RTK), revealed that only five receptors of this family 
(including IR, IGF-1, VEGF and TrkB) were significantly activated by cholesterol loss. Not 
only does this rule out broad and unspecific consequences of cholesterol loss but also comes 
to confirm that different RTKs require different environments for a better signalling (Galbiati 
et al., 1998; Roepstorff et al., 2002). Thus, although cholesterol loss with age will affect a 
number of pathways that converge on the PI3K/Akt pathway and thus modulate survival and 
plasticity by different mechanisms, it appears reasonable to conclude that cholesterol loss 
with age plays a deterministic role in age-associated insulin deficits by, among other possibili-
ties, directly influencing the receptors´ conformation in the plane of the membrane. 
6.  Preventing age-associated brain cholesterol loss rescues insulin-signalling 
deficits 
The cholesterol variations in the brain and the implications for brain health have been 
subjected to studies for years (Pfrieger et al., 2011; Martin et al., 2014a). Cholesterol altera-
tions correlate with different diseases, some of them of hereditary origin and early appear-
ance (demosterolosis, Niemann Pick disease type C) and some of unknown origin and late 
occurrence, like AD. Consequently, numerous laboratories have attempted different types 
of approaches to rescue diseases associated with such variations. For example, one of the 
treatments proposed (and in clinical trial) for Niemann Pick type C disease is based on the 
use of cyclodextrins in order to sequester cholesterol from places with high contents of it. 
This strategy was seen to stop the progress of the disease in animal models (Davidson et 
al., 2009). Another strategy was based on the use of LXR receptor agonists, in order to ac-
tivate cholesterol release from glial cells (see introduction, paragraph 3.1.2). This strategy 
was shown to ameliorate Aβ clearance and to improve memory in AD mouse models (Donkin 
et al., 2010). At the same time and due to the vascular deficits associated to AD (Orsucci 
et al., 2013), the treatment of AD patients with statins for reducing cholesterol levels have 
been tested. However the results of these trials have to be carefully considered. While some 
studies reveal positive results and reduction in dementia progression in human (Wong et 
al., 2013), there are no data to demonstrate that the beneficial effects are due to changes in 
brain cholesterol content. In fact, it is now proposed that any beneficial effect of statins might 
be due to either an improvement in overall brain oxygenation due to the blood cholesterol 
reduction effect of statins or to the anti-inflammatory effect of these compounds or to both. 
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In contraposition to the observed beneficial effects of statins, other clinical studies revealed 
no changes or even cognitive impairment under statin treatments, both in mice and humans 
(Wagstaff et al., 2003; Trompet et al., 2010; Schilling et al., 2014). In this context, the United 
States Federal Drug Administration raised a warning in 2014 about statins’ deleterious effects 
like confusion, memory loss or cognitive impairment, especially in old people. Considering 
that age-associated cholesterol loss in the hippocampus has a negative impact on synaptic 
plasticity (Trovò et al., 2013; Martín et al., 2014b; Palomer et al., 2016b), the last series of 
clinical results and the FDA warning came as no surprise to us. Thus, in order to attempt 
to rescue the reduced insulin signalling of the old we treated mice with a drug that inhibits 
CYP46A1, the enzyme responsible for cholesterol oxidation and removal from brain cells. 
We induced inhibition of CYP46A1 through the oral administration of Voriconazole, which 
significantly reduced the levels of activation of the insulin/IGF-1 downstream pathways, in-
cluding PI3K/Akt and Gsk3β negative phosphorylation, and the inhibitory marks on IRS-1. As 
importantly, Voriconazole also rescued insulin functional signalling (Insulin-LTD).  However, 
it is not clear that this last effect was through the same mechanism that rescues insulin bio-
chemical signs of desensitisation. The Insulin-LTD rescue effect was observed after 1 hour of 
incubation with this drug whereas the effects on the biochemical signs were observed after 
45 days of treatment. We observed that the chronic treatment rescued cholesterol loss of 
the old, allowing us to predict that the biochemical rescue is due to a membrane cholesterol 
restoration. On the other hand, the electrophysiology effects are difficult to see in that same 
context, as they occur too fast to depend on a membrane cholesterol rescue. Instead, it is 
possible that the effects observed at the electrophysiology level are the consequence of a re-
duction in the production of the oxidised cholesterol (24OHC), which was shown to have toxic 
effects (Kölsch et al., 1999 and 2001). Further electrophysiological experiments in long-term 
Voriconazole-treated mice would be required to determine if the functional rescue occurs by 
the cholesterol rescue mechanism. 
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Considering all the results obtained in this thesis we propose the following model for 
the hippocampal insulin/IGF-1 signalling progression with age. In adult mice (7-12 month-old) 
the plasma membrane maintains receptors in a non-activity basal state, which only changes 
upon ligand binding. Under this condition Insulin-LTD and all other functions of insulin and 
IGF-1 (Fig. D2) can progress. In the old mice (20-24 month old) mild but steady loss of cho-
lesterol gradually increases basal level of insulin/IGF-1 receptor activation independently 
from binding to ligand, in the end creating a two-pool IR/IGF-1R receptor environment: insulin 
sensitive and constitutively active. With advanced age, the constitutive active pool increases. 
This last event induces, in concert with other pathways activated by the cholesterol loss phe-
nomenon, a most robust activation of the PI3K/Akt pathway that triggers a series of negative 
events. One of the negative events is the inhibition of insulin/IGF-1 signalling due to the nega-
tive feedback on the IRS-1 scaffold, reducing sensitivity to insulin stimuli. Another negative 
effect is the inhibition of AMPARs internalisation due to Gsk3β inhibition, leading to reduced 
Insulin-LTD (Fig. D3). On the other hand, all what we have just considered “negative” may 
in fact be a evolutionary conserved mechanism to assure survival of old neurons: by reduc-
ing insulin synaptic plasticity mechanisms through the cholesterol loss-mediated (and other) 
mechanisms, cells on the one hand make the survival branch of this pathway more robust 
and, at the same time, reduce a highly energy demanding process such as synaptic transmis-
sion. In this context, it appears as if the worsening of performance that we suffer with age is 
the cost for keeping our neurons alive. We then propose that neurodegenerative diseases of 
the old like Alzheimer´s, associated or not with T2DM, occur because of defects in the sur-
vival mechanisms leading to neuronal death. If this assumption is correct, strategies aimed at 
improving synaptic function based on cholesterol-replenishment strategies might be deleteri-
ous, as they would reduce survival function. These are venues for future studies. 
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Figure D2. Adult mice model for insulin/IGF-1 signalling in the brain. 
The model represents the insulin/IGF-1 signalling pathway in adult mice, where the plasma membrane levels 
of cholesterol are kept at a normal rate, and IR/IGF-1R are activated by their cognate ligands leading to down-
stream signalling in two major directions: PI3K/Akt and MAPK/Erk.
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Figure D3. Old mice model for insulin/IGF-1 signalling in the brain. 
The figure represents the insulin/IGF-1 signalling pathway in old mice. Cholesterol levels are reduced in aged 
mice, possibly (but not exclusively) due to CYP46A1 progressive activation. This situation leads to a higher 
basal activation of IR and IGF-1R, potentiation of PI3K/Akt pathway leading to IRS-1 negative phosphoryla-
tion and consequently insulin/IGF-1 desensitisation and at the same time Gsk3β negative phosphorylation, 
inhibition of neurotransmitter receptor (AMPAR) internalisation and, as consequence, reduced Insulin-LTD. 
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1. The synaptic plasticity event induced by insulin, called insulin-dependent long-term 
depression (Insulin-LTD), is impaired in the hippocampus of old mice.
2. Hyper-activation of the insulin downstream signalling pathway PI3K/Akt is responsible 
for the lack of Insulin-LTD in the old hippocampus. 
3. Hyper-activation of the insulin downstream signalling pathway PI3K/Akt induces insulin 
signalling desensitisation through IRS-1 Serine phosphorylation.
4. Hyper-activation of the insulin downstream effector PI3K/Akt prevents Insulin-LTD by 
Serine 9 phosphorylation on Gsk3β. 
5. In addition to the PI3K/Akt signalling node activation other signalling routes, e.g. inflam-
mation, contribute to age-associated insulin desensitisation via the Jnk and p38 MAPK 
routes. 
6. The higher PI3K/Akt activity in the old mice is in part due to high basal activation state 
of the insulin and the insulin-like growth factor-1 receptors (IR/IGF-1R).
7. The insulin desensitisation observed in old mice hippocampus occurs independently 
from a general, body, defect in insulin signalling.
8. Age-associated cholesterol loss plays a role in old mice hippocampus IR/IGF-1R de-
sensitisation.
9. Cholesterol loss contributes to pathway desensitisation by producing the conforma-
tional changes in IR/IGF-1R required for receptor´s autophosphorylation.
 
10. Prevention of age-associated brain cholesterol loss in vivo by the oral administration 
of a CYP46A1 inhibitor rescues biochemical and functional signs of insulin signalling 
deficits. 
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1. Los eventos de plasticidad sináptica inducidos por insulina, llamados long-term de-
pression (LTD) dependiente de insulina, se encuentran afectados en el hipocampo de 
ratones envejecidos.
2. La elevada actividad de la vía de PI3K/Akt, relacionada con la insulina, es la responsa-
ble de la pérdida de LTD asociada a insulina en el hipocampo de ratones envejecidos.
3. La elevada actividad de la vía asociada a insulina PI3K/Akt causa la pérdida de sensi-
bilidad a insulina a través de la fosforilación en Serinas en IRS-1.
4. La elevada actividad de la vía asociada a insulina PI3K/Akt evita la LTD dependiente 
de insulina a través de la fosforilación en Serina 9 de Gsk3β.
5. Además de la señalización de PI3K/Akt otras vías, como por ejemplo las inflamatorias, 
contribuyen a la pérdida de sensibilidad a insulina asociada al envejecimiento a través 
de las vías de Jnk y p38 MAPKs.
6. La elevada actividad de PI3K/Akt en ratones envejecidos se debe en gran parte a una 
mayor actividad basal de los receptores de insulina e IGF-1 (IR/IGF-1R).
7. La pérdida de sensibilidad a insulina observada en ratones envejecidos es indepen-
diente de un defecto general, en el resto del organismo, de señalización de la insulina.
8. La pérdida de colesterol asociada a la edad juega un papel importante en la reducida 
sensibilidad de IR/IGF-1R en el hipocampo de ratones envejecidos.
9. La pérdida de colesterol contribuye a la disminución de la sensibilidad de la vía cau-
sando los cambios conformacionales en IR/IGF-1R requeridos para la autofosforila-
ción y activación de los receptores.
10. La prevención de la pérdida de colesterol in vivo en cerebro, a través de la adminis-
tración oral de un inhibidor de CYP46A1, rescata los defectos a nivel bioquímico y 
funcionales de la señalización por insulina.
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 - Eck, M. J., Dhe-Paganon, S., Trüb, T., Nolle, R. T., & Shoelson, S. E. (1996). Structure of the IRS-
1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell, 85(5), 695–705. 
 - Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, a L., Normandin, D., 
Cheng, A., Himms-Hagen, J., Chan, C. C., Ramachandran, C., Gresser, M. J., Tremblay, M. L., 
& Kennedy, B. P. (1999). Increased insulin sensitivity and obesity resistance in mice lacking the 
protein tyrosine phosphatase-1B gene. Science (New York, N.Y.), 283(5407), 1544–1548. 
 - Esteban, J. a, Shi, S.-H., Wilson, C., Nuriya, M., Huganir, R. L., & Malinow, R. (2003). PKA phos-
phorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nature 
Neuroscience, 6(2), 136–143. 
 - Evangelisti, E., Zampagni, M., Cascella, R., Becatti, M., Fiorillo, C., Caselli, A., Bagnoli, S., Nac-
mias, B., & Cecchi, C. (2014). Plasma membrane injury depends on bilayer lipid composition in 
Alzheimer’s disease. Journal of Alzheimer’s Disease: JAD, 41(1), 289–300. 
 - Faivre, E., Gault, V. a, Thorens, B., & Hölscher, C. (2011). Glucose-dependent insulinotropic poly-
peptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. 
Journal of Neurophysiology, 105(4), 1574–80. 
 - Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., 
Tanzi, R. E., Selkoe, D. J., Guenette, S. (2003). Insulin-degrading enzyme regulates the levels 
of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in 
vivo. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 
References
119
4162–7. 
 - Favelyukis, S., Till, J. H., Hubbard, S. R., & Miller, W. T. (2001). Structure and autoregulation of the 
insulin-like growth factor 1 receptor kinase. Nature Structural Biology, 8(12), 1058–1063. 
 - Fernandes, M. L., Saad, M. J., & Velloso, L. a. (2001). Effects of age on elements of insulin-sign-
aling pathway in central nervous system of rats. Endocrine, 16(3), 227–234. 
 - Fernandez, A. M., & Torres-Alemán, I. (2012). The many faces of insulin-like peptide signalling in 
the brain. Nature Reviews Neuroscience, 13(4), 225–239. 
 - Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & De Felice, F. G. (2014). Inflammation, defective in-
sulin signaling, and neuronal dysfunction in Alzheimer’s disease. Alzheimer’s and Dementia, 10(1 
SUPPL.), S76–S83. 
 - Fontana, L., Partridge, L., Longo, V. D., & Longo4, V. D. (2010). Extending Healthy Life Span—
From Yeast to Humans. Source: Science, New Series, 328(5976), 321–326. 
 - Freiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., Craft, S., 
De Felice, F. G., & Benedict, C. (2013). Intranasal insulin as a treatment for alzheimer’s disease: 
A review of basic research and clinical evidence. CNS Drugs, 27(7), 505–514. 
 - Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Musch-
ner, D., Thalheimer, A., Türk, A., Hoyer, S., Zöchling, R., Boissl, K. W., Jellinger, K., & Riederer, P. 
(1998). Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. Journal of 
Neural Transmission, 105(4), 423. 
 - Fukumoto, H., Deng, A., Irizarry, M. C., Fitzgerald, M. L., & Rebeck, G. W. (2002). Induction of 
the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists 
increases secreted Aβ levels. Journal of Biological Chemistry, 277(50), 48508–48513. 
 - Fünfschilling, U., Saher, G., Xiao, L., Möbius, W., & Nave, K.-A. (2007). Survival of adult neurons 
lacking cholesterol synthesis in vivo. BMC Neuroscience, 8(1). 
 - Galbiati, F., Volonte, D., Engelman, J. A., Watanabe, G., Burk, R., Pestell, R. G., & Lisanti, M. P. 
(1998). Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyper-
activate the p42/44 MAP kinase cascade. The EMBO Journal, 17(22), 6633–6648. 
 - Garwood, C. J., Ratcliffe, L. E., Morgan, S. V, Simpson, J. E., Owens, H., Vazquez-Villaseñor, 
I., Heath, P. R., Romero, I. A., Ince, P. G., & Wharton, S. B. (2015). Insulin and IGF1 signalling 
pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and 
modulation of the receptors. Molecular Brain, 8, 51. 
 - Gault, V. A., & Hölscher, C. (2008). GLP-1 agonists facilitate hippocampal LTP and reverse the im-
pairment of LTP induced by beta-amyloid. European Journal of Pharmacology, 587(1–3), 112–117. 
 - Giese, K. P., Fedorov, N. B., Filipkowski, R. K., & Silva, A. J. (1998). Autophosphorylation at 
Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science (New York, N.Y.), 
279(5352), 870–873. 
 - Ginsberg, B. H., Jabour, J., & Spector, A. A. (1982). Effect of alterations in membrane lipid un-
saturation on the properties of the insulin receptor of Ehrlich ascites cells. BBA - Biomembranes, 
690(2), 157–164. 
 - Girnita, A., Girnita, L., & Prete, F. (2004). Cyclolignans as Inhibitors of the Insulin-Like Growth Fac-
References
120
tor-1 Receptor and Malignant Cell Growth. Cancer Research, 64(22), 236–242. 
 - Glynn, P. (2013). Neuronal phospholipid deacylation is essential for axonal and synaptic integrity. 
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1831(3), 633–641. 
 - Goldberg, D. M., & Riordan, J. R. (1986). Role of membranes in disease. Clinical Physiology and 
Biochemistry, 4(5), 305–336.
 - Gould, G. W., Brant, A. M., Kahn, B. B., Shepherd, P. R., McCoid, S. C., & Gibbs, E. M. (1992). 
Expression of the brain-type glucose transporter is restricted to brain and neuronal cells in mice. 
Diabetologia, 35(4), 304–309.
 - Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O’Connor, R., & 
O’Neill, C. (2005). Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss 
and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. Journal of 
Neurochemistry, 93(1), 105–117. 
 - Gulati, N., Laudet, B., Zohrabian, V. M., Murali, R., & Jhanwar-Uniyal, M. (2006). The antiprolif-
erative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. 
Anticancer Research, 26(2 A), 1177–1181.
 - Hannah, M. J., Schmidt, A. a, & Huttner, W. B. (1999). Synaptic vesicle biogenesis. Machinery, 
15, 733–98. 
 - He, Q., & Meiri, K. F. (2002). Isolation and characterization of detergent-resistant microdomains 
responsive to NCAM-mediated signaling from growth cones. Molecular and Cellular Neuroscienc-
es, 19(1), 18–31. 
 - Hetman, M., Cavanaugh, J. E., Kimelman, D., & Xia, Z. (2000). Role of glycogen synthase kinase-
3beta in neuronal apoptosis induced by trophic withdrawal. The Journal of Neuroscience: The 
Official Journal of the Society for Neuroscience, 20(7), 2567–2574.
 - Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamis-
ligil, G. S. (2002). A central role for JNK in obesity and insulin resistance. Nature, 420(6913), 
333–336. 
 - Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Géloën, A., Even, P. C., Cervera, P., & Le 
Bouc, Y. (2003). IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Na-
ture, 421(January), 182–187. 
 - Hsu, C.-C., Wahlqvist, M. L., Lee, M.-S., & Tsai, H.-N. (2011). Incidence of dementia is increased 
in type 2 diabetes and reduced by the use of sulfonylureas and metformin. Journal of Alzheimer’s 
Disease: JAD, 24(3), 485–493. 
 - Hu, D., Serrano, F., Oury, T. D., & Klann, E. (2006). Aging-Dependent Alterations in Synaptic Plas-
ticity and Memory in Mice That Overexpress Extracellular Superoxide Dismutase. J. Neurosci., 
26(15), 3933–3941. 
 - Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007). Type 2 Diabetes and the 
Risk of Parkinson’s Disease. Diabetes Care, 30(4), 842–847. 
 - Huang, C. C., You, J. L., Lee, C. C., & Hsu, K. Sen. (2003). Insulin induces a novel form of postsyn-
aptic mossy fiber long-term depression in the hippocampus. Molecular and Cellular Neuroscience, 
24(3), 831–841. 
References
121
 - Huang, C.-C., Lee, C.-C., & Hsu, K.-S. (2004). An investigation into signal transduction mecha-
nisms involved in insulin-induced  long-term depression in the CA1 region of the hippocampus. 
Journal of Neurochemistry, 89(1), 217–231. 
 - Huang, C.-C., Lee, C.-C., & Hsu, K.-S. (2009). The role of insulin receptor signaling in synaptic 
plasticity and cognitive function. Chang Gung Medical Journal, 33(2), 115–25. 
 - Hubbard, S. R., Wei, L., Ellis, L., & Hendrickson, W. A. (1994). Crystal structure of the tyrosine 
kinase domain of the human insulin receptor. Nature, 372(6508), 746–754. 
 - Hubbard, S. R. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in com-
plex with peptide substrate and ATP analog. EMBO Journal, 16(18), 5572–5581. 
 - Ikonen, E. (2008). Cellular cholesterol trafficking and compartmentalization. Nature Reviews. Mo-
lecular Cell Biology, 9(2), 125–138. 
 - Izumi, Y., Yamada, K. A., Matsukawa, M., & Zorumski, C. F. (2003). Effects of insulin on long-term 
potentiation in hippocampal slices from diabetic rats. Diabetologia, 46(7), 1007–1012. 
 - Jahn, R., & Sudhof, T. (1999). Membrane fusion and exocytosis. Annual Reviews in Biochemistry, 
68(1), 863-911. 
 - Jiang, G., Dallas-Yang, Q., Biswas, S., Li, Z., & Zhang, B. B. (2004). Rosiglitazone, an agonist of 
peroxisome-proliferator-activated receptor γ (PPARγ), decreases inhibitory serine phosphorylation 
of IRS1 in vitro and in vivo. Biochem. J, 377, 339–346. 
 - Kabayama, K., Sato, T., Kitamura, F., Uemura, S., Won Kang, B., Igarashi, Y., & Inokuchi, J. I. 
(2005). TNFα-induced insulin resistance in adipocytes as a membrane microdomain disorder: 
Involvement of ganglioside GM3. Glycobiology, 15(1), 21–29. 
 - Kabayama, K., Sato, T., Saito, K., Loberto, N., Prinetti, A., Sonnino, S., Kinjo, M., Igarashi, Y., & 
Inokuchi, J. (2007). Dissociation of the insulin receptor and caveolin-1 complex by ganglioside 
GM3 in the state of insulin resistance. Proceedings of the National Academy of Sciences of the 
United States of America, 104(34), 13678–13683. 
 - Kaech, S., & Banker, G. (2006). Culturing hippocampal neurons. Nature Protocols, 1(5), 2406–
2415. 
 - Kanety, H., Feinstein, R., Papa, M. Z., Hemi, R., & Karasik, A. (1995). Tumor necrosis factor 
α-induced phosphorylation of insulin receptor substrate-1 (IRS-1). The Journal of Biological Chem-
istry, 270(40), 23780–23784. 
 - Kavran, J. M., McCabe, J. M., Byrne, P. O., Connacher, M. K., Wang, Z., Ramek, A., Sarabipour, 
S., Shan, Y., Shaw, D. E., Hristova, K., Cole, P. A., & Leahy, D. J. (2014). How IGF-1 activates its 
receptor. eLife, 3(Id), e03772. 
 - Kern, W., Peters, A., Fruehwald-Schultes, B., Deininger, E., Born, J., & Fehm, H. L. (2001). Improv-
ing influence of insulin on cognitive functions in humans. Neuroendocrinology, 74(4), 270–280. 
 - Kim, A. H., Yano, H., Cho, H., Meyer, D., Monks, B., Margolis, B., Birnbaum, M. J., & Chao, M. V. 
(2002). Akt1 regulates a JNK scaffold during excitotoxic apoptosis. Neuron, 35(4), 697–709. 
 - Kleinridders, A., Schenten, D., Könner, A. C., Belgardt, B. F., Mauer, J., Okamura, T., Wunderlich, 
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